Antigen-binding molecules that specifically bind to DLL3 and CD3 and their pharmaceutical uses

Abstract

The present disclosure relates to an antigen-binding molecule that specifically binds to DLL3 and CD3 and its pharmaceutical use, and the antigen-binding molecule can be used for the treatment of cancer.

Description

Technical Field

[0001] The present disclosure belongs to the field of biotechnology, and more specifically, relates to DLL3 / CD3 antigen-binding molecules and their uses.

Background Art

[0002] The descriptions herein do not necessarily constitute prior art, but only provide background information related to the present disclosure.

[0003] Small cell lung cancer (SCLC) belongs to a relatively malignant type of lung cancer that accounts for 10% - 15% of all lung cancer cases. Small cell lung cancer has a fast tumor growth rate, is prone to metastasis, and has a 5-year survival rate of less than 7%. The therapeutic drugs for small cell lung cancer are relatively limited, mainly chemotherapy agents. For example, chemotherapy using a combination of platinum-based / etoposide is used. Small cell lung cancer patients respond well to chemotherapy in the early stage, but are extremely prone to drug resistance and recurrence. In recent years, immunotherapies, such as PD-L1 antibody and PD1 antibody, have a slight effect on SCLC patients, but the effective rate is about 15%. Currently, specific targeted therapeutic drugs have not yet been developed.

[0004] DLL3 is one of the ligands that inhibit Notch. In the normal state, DLL3 is in the Golgi apparatus, but in cancer cells (e.g., small cell lung cancer cells), DLL3 is expressed on the cell surface. DLL3 binds cis to Notch and inhibits cell-cell binding and the endocytosis of Notch into target cells, thereby suppressing the Notch signaling pathway and promoting the growth of tumor cells. DLL3 is mainly expressed in neural or neuroendocrine tumors, including small cell lung cancer, large cell neuroendocrine carcinoma, gastrointestinal neuroendocrine tumors, small cell bladder cancer, glioblastoma multiforme, metastatic castration-resistant prostate cancer, melanoma, etc. In particular, in SCLC, more than 80% of SCLC shows positive expression of DLL3, but it is not expressed in normal lung tissue and tissue adjacent to the cancer. Due to this difference in expression, DLL3 is an extremely potential therapeutic target for treating SCLC.

[0005] CD3 is a homodimeric or heterodimeric antigen expressed on T cells. Functional CD3 is formed by the dimerization of two out of four different chains, namely ε, ζ, δ, and γ. CD3 dimer sequences include γ / ε, δ / ε, and ζ / ζ. CD3 binds to the T cell receptor complex (TCR) and is necessary for T cell activation. Therefore, the use of anti-CD3 antibodies that activate T cells has been proposed for the treatment of cancer. However, administration of anti-CD3 antibodies can trigger T cell activation and related cytokine release, and excessive cytokine release causes severe cytokine release syndrome (CRS), which is an important issue for anti-CD3 antibodies in clinical administration. SUMMARY OF THE INVENTION

[0006] The present disclosure provides an antigen-binding molecule that specifically binds to DLL3 and CD3.

[0007] In one aspect, the present disclosure provides an antigen-binding molecule that includes at least one antigen-binding module that specifically binds to DLL3 and at least one antigen-binding module that specifically binds to CD3. The antigen-binding module that specifically binds to DLL3 includes a heavy chain variable region DLL3-VH and a light chain variable region DLL3-VL, and the antigen-binding module that specifically binds to CD3 includes a heavy chain variable region CD3-VH and a light chain variable region CD3-VL.

[0008] In some embodiments, the above antigen-binding molecule, among which, (i) DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH include the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 12, 56, or 57, respectively, and DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL include the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 13, 63, 64, 65, 66, or 67, respectively, or (ii) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 14, 79, 80, 81, or 82, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 15, or (iii) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 16, 91, 92, 93, or 94, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 17, or (iv) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 18, 107, 108, 109, 110, 112, 113, 114, or 115, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 19.

[0009] In some embodiments, the above antigen-binding molecule, among which, (i) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 12, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 13, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 54, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 64, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 54, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 63, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 56, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 65, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 56, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 66, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 56, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 67, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 57, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 65, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 57, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 66, or DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 57, and DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 67, or (ii) DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 14, and DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 15, or DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 81, and DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 77, or DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NOs: 79, 80, or 82, and DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 77, or (iii) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 16, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 17, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 91, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 87, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 92, 93, or 94, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 87, or (iv) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 18, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 19, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 109, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 100, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 107, 108, 110, 112, 113, 114, or 115, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 100.

[0010] In some embodiments, the above DLL3-HCDR1, DLL3-HCDR2, DLL3-HCDR3, DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 are defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering rules.

[0011] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, i) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69, or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, 71, 72, or 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25 or 74, or ii) The above DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 26 or 84, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 27 or 85, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 28 or 83, and the above DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 31, or iii) The above DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 32, 96, 97, 98 or 99, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 36, or iv) The above DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 37, 117, 118, 119 or 120, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 40.

[0012] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74.

[0013] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25.

[0014] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 28, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31.

[0015] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, or the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 97, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, or the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 98, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 99, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36.

[0016] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40, or the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 117, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40, or the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 118, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 120, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40.

[0017] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25.

[0018] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25.

[0019] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31.

[0020] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36.

[0021] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40.

[0022] In some embodiments, it is an antigen-binding molecule according to any one of the above, wherein the DLL3-HCDR1, DLL3-HCDR2, DLL3-HCDR3, DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 are defined according to the Kabat numbering rules.

[0023] In some embodiments, the antigen-binding molecule described in any one of the above has a KD of less than 4×10 -9 M, 3×10 -9 M, 2×10 -9 M, 1×10 -9 M, 9×10 -10 M, 8×10 -10 M, 7×10 -10 M, 6×10 -10 M, 5×10 -10 M, 4×10 -10 M, 3×10 -10 M, 2×10 -10 M, 1×10 -10 M, 9×10 -11 M and binds to human DLL3, and the KD is measured by surface plasmon resonance method.

[0024] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the DLL3-VH and DLL3-VL are humanized and contain the FR regions of human antibodies.

[0025] In some embodiments, the antigen-binding molecule described in any one of the above, wherein (i) the DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the FR region of the DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A, and the DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, 71, 72 or 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25 or 74, and the FR region of the DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or (ii) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26 or 84, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27 or 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 28 or 83, and The above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y, or (iii) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 32, 96, 97, 98, or 99, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 24T, 44S, 71V, and 73K, and The above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 9K, 43S, 68A, and 85D, or (iv) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 37, 117, 118, 119, or 120, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 3R, 5Q, 7F, 9P, 10V, 12V, 40S, 41H, 44S, 48I, 67A, 69L, 71V, 73K, 75S, and 83T, and The above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40, and the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 9K, 43S, 60D, 68A, 87H, and 100S.

[0026] In some embodiments, it is the antigen-binding molecule described in any one of the above, which binds to human DLL3 with a KD of less than 4×10 -9 M, 3×10 -9 M, 2×10 -9 M, 1×10 -9 M, 9×10 -10 M, 8×10 -10 M, 7×10 -10 M, 6×10 -10 M, 5×10 -10 M, 4×10 -10 M, 3×10 -10 M, 2×10 -10 M, 1×10 -10 M, 9×10 -11 M, and the above KD is measured by surface plasmon resonance.

[0027] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69, or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D.

[0028] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D.

[0029] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 28, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y.

[0030] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 24T, 44S, 71V, and 73K, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36. And the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 9K, 43S, 68A, and 85D.

[0031] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 3R, 5Q, 7F, 9P, 10V, 12V, 40S, 41H, 44S, 48I, 67A, 69L, 71V, 73K, 75S and 83T, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40, and the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 9K, 43S, 60D, 68A, 87H and 100S.

[0032] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, the above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0033] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above CD3-VH has CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 135, and the above CD3-VL has CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0034] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 50 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of Q1E, Q43K, M48I, V67A, I69L, R71V, T73K, and S76N in the FR region of SEQ ID NO: 50.

[0035] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 51 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of Q1E, 5Q, R38K, V68A, F69L, L71V, T73K, V75S, and S76N in the FR region of SEQ ID NO: 51.

[0036] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 52 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of F27Y, S30T, I69L, R71V, D73K, and T93A in the FR region of SEQ ID NO: 52.

[0037] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 62 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of F36L, A43S, P44F, S46G, T69A, F71Y, and T85D in the FR region of SEQ ID NO: 62.

[0038] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 68 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of Y36L, Q42K, L46G, T69A, F71Y, E79Q, and V85D in the FR region of SEQ ID NO: 68.

[0039] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 78 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 78.

[0040] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 75 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of K42G, P44V, and F71Y in the FR region of SEQ ID NO: 75.

[0041] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 95 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of Q1E, A24T, R44S, R71V, and T73K in the FR region of SEQ ID NO: 95.

[0042] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 88 or a variant thereof. In some embodiments, the above variant contains one or more amino acid substitutions selected from the group consisting of D1N, D9K, P43S, G68A, and V85D in the FR region of SEQ ID NO: 88.

[0043] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 116 or a variant thereof. In some embodiments, the above variant contains one or more amino acid substitutions selected from the group consisting of Q1E, Q3R, V5Q, S7F, A9P, E10V, K12V, A40S, P41H, R44S, M48I, V67A, I69L, R71V, T73K, A75S, and R83T in the FR region of SEQ ID NO: 116.

[0044] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100 or a variant thereof. In some embodiments, the above variant contains one or more amino acid substitutions selected from the group consisting of D9K, P43S, G68A, and Y87H in the FR region of SEQ ID NO: 100.

[0045] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 103 or a variant thereof. In some embodiments, the above variant contains one or more amino acid substitutions selected from the group consisting of A43S, S60D, and Q100S in the FR region of SEQ ID NO: 103.

[0046] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 56.

[0047] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 57.

[0048] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 63, and in some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of A43S and P44F.

[0049] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 64 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 64, and in some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of A43S and P44F.

[0050] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 65 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 65, and in some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of A43S and P44F.

[0051] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 66 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 66. In some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of A43S and P44F.

[0052] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 67 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 67.

[0053] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 79, 80, 81 or 82, or a variant of SEQ ID NO: 79, 80, 81 or 82. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 79, 80, 81 or 82, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 75 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of K42G, P44V and F71Y in the FR region of SEQ ID NO: 75.

[0054] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, 92, 93 or 94, or a variant of SEQ ID NO: 91, 92, 93 or 94. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 91, 92, 93 or 94, and The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 88 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of D1N, D9K, P43S, G68A, and V85D in the FR region of SEQ ID NO: 88.

[0055] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 107, 108, 109, or 110, or a variant of SEQ ID NO: 107, 108, 109, or 110. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 107, 108, 109, or 110, and in some embodiments, the amino acid substitutions are one or more amino acid substitutions selected from the group consisting of V5Q, S7F, A9P, E10V, K12V, A40S, P41H, M48I, V67A, A75S, and R83T.

[0056] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 112, or a variant of SEQ ID NO: 112. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 112, and in some embodiments, the amino acid substitutions are one or more amino acid substitutions selected from the group consisting of V5Q, A9P, K12V, A40S, P41H, 4M8I, V67A, and R83T.

[0057] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 113 or a variant of SEQ ID NO: 113. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 113. In some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of V5Q, S7F, A9P, E10V, K12V, A40S, P41H, A75S, and R83T.

[0058] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 114 or a variant of SEQ ID NO: 114. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 114. In some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of V5Q, S7F, A9P, E10V, K12V, M48I, V67A, A75S, and R83T.

[0059] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 115 or a variant of SEQ ID NO: 115. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 115. In some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of V5Q, A9P, K12V, A40S, P41H, M48I, and V67A.

[0060] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of D9K, P43S, G68A, and Y87H in the FR region of SEQ ID NO: 100.

[0061] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 103 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of A43S, S60D, and Q100S in the FR region of SEQ ID NO: 103.

[0062] In some embodiments, the antigen-binding molecule according to any one of the above, among which, i) the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 12, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 13, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, or ii) the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 14, 78, 79, 80, 81, 82, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 15, 75, 76, 77, or iii) the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 16, 89, 90, 91, 92, 93, 94, 95, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 17, 86, 87, 88, or iv) the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 18, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 19, 100, 101, 102, 103, 104.

[0063] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 43, 44, or 45, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 58, 59, or 60, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 47, 48, 49, 53, 54 or 55, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 59, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 43, 44 or 45, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 60, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 46, 48, 53, 54 or 55, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 61, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63 or 64, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56 or 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, 66 or 67.

[0064] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 78 or 79, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 75, 76 or 77, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 78, 79, 80, 81 or 82, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 77.

[0065] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 89, 90, 91, 92, 93 or 94, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 86 or 87, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 95, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 87.

[0066] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 105, 106, 107, 108, 109, 110 or 111, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100, 101 or 102, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 112, 113, 114 or 115, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100, 103 or 104, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 103.

[0067] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, i) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 61, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 64, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, or ii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 77, or iii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 87, or iv) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100.

[0068] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, i) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 12, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 13, or ii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 14, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 15, or iii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 16, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 17, or iv) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 18, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 19.

[0069] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63.

[0070] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 61.

[0071] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 77.

[0072] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 87.

[0073] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100.

[0074] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above CD3-VH contains the amino acid sequence of SEQ ID NO: 136, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0075] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above CD3-VH contains the amino acid sequence of SEQ ID NO: 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0076] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, the antigen-binding module that specifically binds to the above DLL3 or the antigen-binding module that specifically binds to the above CD3 includes a Titin chain and an Obscurin chain capable of forming a dimer.

[0077] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, the antigen-binding module that specifically binds to the above DLL3 includes a Titin chain and an Obscurin chain capable of forming a dimer.

[0078] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding module that specifically binds to the above CD3 includes a Titin chain and an Obscurin chain capable of forming a dimer.

[0079] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the Titin chain includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 192 to 210, and the Obscurin chain includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 211 to 251.

[0080] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the Titin chain includes the amino acid sequence of SEQ ID NO: 208.

[0081] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the Obscurin chain includes the amino acid sequence of SEQ ID NO: 246.

[0082] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the Titin chain includes the amino acid sequence of SEQ ID NO: 208, and the Obscurin chain includes the amino acid sequence of SEQ ID NO: 246.

[0083] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule includes an Fc region.

[0084] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule includes a human IgG Fc region.

[0085] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule includes a human IgG1 Fc region.

[0086] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises an Fc region, and the Fc region comprises amino acid substitutions capable of reducing the binding of one or more Fc regions to Fcγ receptors.

[0087] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises an Fc region, and the Fc region is a human IgG1 Fc region, and the amino acids at positions 234 and 235 are A, numbered according to the EU index.

[0088] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises an Fc region, and the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that can associate with each other, and Fc1 and Fc2 each independently have amino acid substitutions that reduce the homodimerization of one or more Fc regions.

[0089] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises an Fc region, and the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that can associate with each other, Fc1 has a knob structure by the knob-in-hole technology, and Fc2 has a hole structure by the knob-in-hole technology.

[0090] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises an Fc region, and the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that can associate with each other, Fc1 has a knob structure by the knob-in-hole technology, and Fc2 has a hole structure by the knob-in-hole technology, the amino acid at position 366 of Fc1 is W, and the amino acids at positions 366, 368, and 407 of Fc2 are S, A, and V, respectively, numbered according to the EU index.

[0091] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule comprises an Fc region, the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that can associate with each other, the Fc1 has a knob structure by the knob-in-hole technology, and the Fc2 has a hole structure by the knob-in-hole technology, wherein the amino acid at position 354 of the Fc1 is C, and the amino acid at position 366 is W, and the amino acid at position 349 of the Fc2 is C, the amino acid at position 366 is S, the amino acid at position 368 is A, and the amino acid at position 407 is V, numbered according to the EU index.

[0092] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule comprises an Fc region, the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that can associate with each other, wherein the Fc1 comprises the amino acid sequence of SEQ ID NO: 143, and the Fc2 comprises the amino acid sequence of SEQ ID NO: 144.

[0093] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule comprises an Fc region, the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that can associate with each other, wherein the amino acid at position 349 of the Fc1 is C, the amino acid at position 366 is W, and the amino acid at position 237 is A, and the amino acid at position 354 of the Fc2 is C, the amino acid at position 366 is S, the amino acid at position 368 is A, the amino acid at position 407 is V, and the amino acid at position 237 is A, numbered according to the EU index.

[0094] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule comprises an Fc region, the Fc region comprises a first subunit Fc1 and a second subunit Fc2 that can associate with each other, wherein the Fc1 comprises the amino acid sequence of SEQ ID NO: 145, and the Fc2 comprises the amino acid sequence of SEQ ID NO: 146.

[0095] In the present disclosure, ordinal numbers such as "first", "second", "Formula a", "Formula b", "Fc1", "Linker 3", etc. are merely used to distinguish different technical features, elements, components, and steps, and should not be understood as intending to limit levels, orders, or quantities.

[0096] In some embodiments, it is an antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule includes one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3.

[0097] In some embodiments, it is an antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule includes one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3, among which, the antigen-binding module that specifically binds to the above DLL3 is a Fab, and the antigen-binding module that specifically binds to the above CD3 is a substituted Fab including a Titin chain and an Obscurin chain capable of forming a dimer.

[0098] In some embodiments, it is an antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule includes one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3, among which, the antigen-binding module that specifically binds to the above CD3 is a Fab, and the antigen-binding module that specifically binds to the above DLL3 is a substituted Fab including a Titin chain and an Obscurin chain capable of forming a dimer.

[0099] In some embodiments, it is an antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule includes one first chain having a structure represented by formula (a), one second chain having a structure represented by formula (b), one third chain having a structure represented by formula (c), and one fourth chain having a structure represented by formula (d). (a) [DLL3-VH]-[Linker 1]-[Titin chain] / [Obscurin chain]-[Fc2] / [Fc1], (b) [DLL3-VL]-[Linker 2]-[Obscurin chain] / [Titin chain], (c) [CD3-VH]-[CH1]-[Fc1] / [Fc2], (d) [CD3-VL]-[CL], and among them, the above Linker 1 and the above Linker 2 are the same or different peptide linkers, and the structures represented by formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus. " / " indicates "or", that is, Fc1 and Fc2 may be interchanged in position, and the Titin chain and the Obscurin chain may be interchanged in position.

[0100] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain having the structure represented by formula (a), one second chain having the structure represented by formula (b), one third chain having the structure represented by formula (c), and one fourth chain having the structure represented by formula (d), (a) [DLL3-VH]-[Linker 1]-[Titin chain]-[Fc2], (b) [DLL3-VL]-[Linker 2]-[Obscurin chain], (c) [CD3-VH]-[CH1]-[Fc1], (d) [CD3-VL]-[CL], and among them, the above Linker 1 and the above Linker 2 are the same or different peptide linkers, and the structures represented by formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus, and Fc1 and Fc2 may be interchanged in position, and the Titin chain and the Obscurin chain may be interchanged in position.

[0101] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (a), one second chain having a structure represented by formula (b), one third chain having a structure represented by formula (c), and one fourth chain having a structure represented by formula (d). (a) [DLL3-VH]-[Linker 1]-[Titin chain]-[Fc2], (b) [DLL3-VL]-[Linker 2]-[Obscurin chain], (c) [CD3-VH]-[CH1]-[Fc1], (d) [CD3-VL]-[CL], and wherein the Linker 1 and the Linker 2 are the same or different peptide linkers, and the structures represented by formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus.

[0102] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (a'), one second chain having a structure represented by formula (b'), one third chain having a structure represented by formula (c'), and one fourth chain having a structure represented by formula (d'). (a') [CD3-VH]-[Linker 1]-[Titin chain / Obscurin chain]-[Fc2 / Fc1], (b') [CD3-VL]-[Linker 2]-[Obscurin chain / Titin chain], (c') [DLL3-VH]-[CH1]-[Fc1 / Fc2], (d') [DLL3-VL]-[CL], and wherein the Linker 1 and the Linker 2 do not exist, that is, both the Linker 1 and the Linker 2 are peptide bonds, and the structures represented by formulas (a'), (b'), (c') and (d') are arranged from the N-terminus to the C-terminus. " / " indicates "or", that is, Fc1 and Fc2 may be interchanged in position, and the Titin chain and the Obscurin chain may be interchanged in position.

[0103] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (a’), one second chain having a structure represented by formula (b’), one third chain having a structure represented by formula (c’), and one fourth chain having a structure represented by formula (d’), (a’) [CD3-VH]-[Linker 1]-[Titin chain]-[Fc2], (b’) [CD3-VL]-[Linker 2]-[Obscurin chain], (c’) [DLL3-VH]-[CH1]-[Fc1], (d’) [DLL3-VL]-[CL], wherein the Linker 1 and the Linker 2 are absent, i.e., both the Linker 1 and the Linker 2 are peptide bonds, and the structures represented by formulas (a’), (b’), (c’) and (d’) are arranged from the N-terminus to the C-terminus, and Fc1 and Fc2 may be interchanged in position, and the Titin chain and the Obscurin chain may be interchanged in position.

[0104] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (a), one second chain having a structure represented by formula (b), one third chain having a structure represented by formula (c), and one fourth chain having a structure represented by formula (d), (a’) [CD3-VH]-[Linker 1]-[Titin chain]-[Fc2], (b’) [CD3-VL]-[Linker 2]-[Obscurin chain], (c’) [DLL3-VH]-[CH1]-[Fc1], (d’) [DLL3-VL]-[CL], wherein the Linker 1 and the Linker 2 are absent, i.e., both the Linker 1 and the Linker 2 are peptide bonds, and the structures represented by formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus.

[0105] In some embodiments, an antigen-binding molecule according to any one of the above, wherein the DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 25, and the CD3-VH has a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131 or 135, and the CD3-VL has a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0106] In some embodiments, an antigen-binding molecule according to any one of the above, wherein the DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 25, and the CD3-VH has a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131, and the CD3-VL has a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0107] In some embodiments, an antigen-binding molecule as described in any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, and the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0108] In some embodiments, an antigen-binding molecule as described in any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, and the above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0109] In some embodiments, an antigen-binding molecule as described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, and The above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0110] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, and The above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0111] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, and the above CD3-VH has a CD3-HCDR first containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0112] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40, and the above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0113] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, and the above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0114] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 61, and the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0115] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63, and the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0116] In some embodiments, the antigen-binding molecule according to any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0117] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 77. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0118] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 87. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0119] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0120] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 87. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0121] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the Titin chain and the Obscurin chain are any of the Titin chain and the Obscurin chain capable of forming a dimer in Tables 3-1 and 3-2 in the present disclosure. In some embodiments, the antigen-binding molecule described in any one of the above, wherein the Titin chain contains the amino acid sequence of SEQ ID NO: 208. In some embodiments, the antigen-binding molecule described in any one of the above, wherein the Obscurin chain contains the amino acid sequence of SEQ ID NO: 246.

[0122] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the Linker 1 and Linker 2 are both peptide linkers known in the art as long as the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker may be a flexible peptide having 1 to 50 or 3 to 20 amino acid residues. In some embodiments, the length of the peptide linker is 3 to 15 amino acid residues. In some embodiments, the peptide Linker 1 and Linker 2 each independently have the structure of (GGGGS)n, wherein n is 1, 2, or 3. In some embodiments, the sequences of Linker 1 and Linker 2 are both GGGGS (SEQ ID NO: 147).

[0123] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the CH1 is the CH1 sequence of IgG. In some embodiments, the CH1 is the CH1 of IgG1. In some embodiments, the CH1 contains the amino acid sequence of SEQ ID NO: 141.

[0124] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the CL is the constant region of the light chain of an antibody. In some embodiments, the antigen-binding molecule described in any one of the above, wherein the CL is the constant region of the light chain of the kappa chain or the lambda chain. In some embodiments, the CL includes the amino acid sequence of SEQ ID NO: 142.

[0125] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule One first chain comprising the amino acid sequence of SEQ ID NO: 171, one second chain comprising the amino acid sequence of SEQ ID NO: 172, one third chain comprising the amino acid sequence of SEQ ID NO: 154, one fourth chain comprising the amino acid sequence of SEQ ID NO: 155, or One first chain comprising the amino acid sequence of SEQ ID NO: 171, one second chain comprising the amino acid sequence of SEQ ID NO: 172, one third chain comprising the amino acid sequence of SEQ ID NO: 156, one fourth chain comprising the amino acid sequence of SEQ ID NO: 155, or One first chain comprising the amino acid sequence of SEQ ID NO: 152, one second chain comprising the amino acid sequence of SEQ ID NO: 153, one third chain comprising the amino acid sequence of SEQ ID NO: 154, one fourth chain comprising the amino acid sequence of SEQ ID NO: 155, or One first chain comprising the amino acid sequence of SEQ ID NO: 152, one second chain comprising the amino acid sequence of SEQ ID NO: 153, one third chain comprising the amino acid sequence of SEQ ID NO: 156, one fourth chain comprising the amino acid sequence of SEQ ID NO: 155, or One first chain comprising the amino acid sequence of SEQ ID NO: 164, one second chain comprising the amino acid sequence of SEQ ID NO: 165, one third chain comprising the amino acid sequence of SEQ ID NO: 154, one fourth chain comprising the amino acid sequence of SEQ ID NO: 155, or One first chain comprising the amino acid sequence of SEQ ID NO: 164, one second chain comprising the amino acid sequence of SEQ ID NO: 165, one third chain comprising the amino acid sequence of SEQ ID NO: 156, one fourth chain comprising the amino acid sequence of SEQ ID NO: 155, or One first chain comprising the amino acid sequence of SEQ ID NO: 178, one second chain comprising the amino acid sequence of SEQ ID NO: 179, one third chain comprising the amino acid sequence of SEQ ID NO: 154, one fourth chain comprising the amino acid sequence of SEQ ID NO: 155, or comprises one first chain comprising the amino acid sequence of SEQ ID NO: 178, one second chain comprising the amino acid sequence of SEQ ID NO: 179, one third chain comprising the amino acid sequence of SEQ ID NO: 156, and one fourth chain comprising the amino acid sequence of SEQ ID NO: 155.

[0126] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain comprising the amino acid sequence of SEQ ID NO: 171, one second chain comprising the amino acid sequence of SEQ ID NO: 172, one third chain comprising the amino acid sequence of SEQ ID NO: 154, and one fourth chain comprising the amino acid sequence of SEQ ID NO: 155.

[0127] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3. The antigen-binding module that specifically binds to DLL3 is a Fab, and the antigen-binding module that specifically binds to CD3 is a scFv. In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (e), one second chain having a structure represented by formula (f), and one third chain having a structure represented by formula (g), (e) [DLL3-VL]-[CL], (f) [DLL3-VH]-[CH1]-[Fc2] / [Fc1], (g) [CD3-VH]-[linker 3]-[CD3-VL]-[linker 4]-[Fc1] / [Fc2], and wherein the linker 3 and the linker 4 are the same or different peptide linkers, The structures represented by formulas (e), (f), and (g) are arranged from the N-terminus to the C-terminus. " / " indicates "or", that is, Fc1 and Fc2 may be interchanged in position.

[0128] In some embodiments, it is an antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (e), one second chain having a structure represented by formula (f), and one third chain having a structure represented by formula (g). (e) [DLL3-VL]-[CL], (f) [DLL3-VH]-[CH1]-[Fc2], (g) [CD3-VH]-[linker 3]-[CD3-VL]-[linker 4]-[Fc1], wherein the linker 3 and the linker 4 are the same or different peptide linkers. The structures represented by formulas (e), (f), and (g) are arranged from the N-terminus to the C-terminus, and Fc1 and Fc2 may be interchanged in position.

[0129] In some embodiments, it is an antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (e), one second chain having a structure represented by formula (f), and one third chain having a structure represented by formula (g). (e) [DLL3-VL]-[CL], (f) [DLL3-VH]-[CH1]-[Fc2], (g) [CD3-VH]-[linker 3]-[CD3-VL]-[linker 4]-[Fc1], wherein the linker 3 and the linker 4 are the same or different peptide linkers. The structures represented by formulas (e), (f), and (g) are arranged from the N-terminus to the C-terminus.

[0130] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3, the antigen-binding module that specifically binds to DLL3 is an scFv, and the antigen-binding module that specifically binds to CD3 is a Fab.

[0131] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (e’), one second chain having a structure represented by formula (f’), and one third chain having a structure represented by formula (g’). (e’)[CD3-VL]-[CL], (f’)[CD3-VH]-[CH1]-[Fc2] / [Fc1], (g’)[DLL3-VH]-[linker 3]-[DLL3-VL]-[linker 4]-[Fc1] / [Fc2], where the linker 3 and the linker 4 are the same or different peptide linkers. The structures represented by formulas (e’), (f’), and (g’) are arranged in sequence from the N-terminus to the C-terminus. " / " indicates "or".

[0132] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (e’), one second chain having a structure represented by formula (f’), and one third chain having a structure represented by formula (g’). (e’)[CD3-VL]-[CL], (f’)[CD3-VH]-[CH1]-[Fc2], (g’)[DLL3-VH]-[linker 3]-[DLL3-VL]-[linker 4]-[Fc1], where the linker 3 and the linker 4 are the same or different peptide linkers. The structures represented by formulas (e’), (f’), and (g’) are arranged from the N-terminus to the C-terminus, and Fc1 and Fc2 may be interchanged in position.

[0133] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one first chain having a structure represented by formula (e’), one second chain having a structure represented by formula (f’), and one third chain having a structure represented by formula (g’). (e’)[CD3-VL]-[CL], (f’)[CD3-VH]-[CH1]-[Fc2], (g’)[DLL3-VH]-[linker 3]-[DLL3-VL]-[linker 4]-[Fc1], wherein the linker 3 and the linker 4 are the same or different peptide linkers. The structures represented by formulas (e’), (f’), and (g’) are arranged from the N-terminus to the C-terminus.

[0134] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the DLL3-VH has DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL has DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 25, and the CD3-VH has CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131 or 135, and the CD3-VL has CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0135] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 31, and the above CD3-VH has a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0136] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 36, and the above CD3-VH has a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0137] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40, and the above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0138] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, and The above CD3-VH has a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 135, and the above CD3-VL has a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0139] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH comprises the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL comprises the amino acid sequence of SEQ ID NO: 61, and the above CD3-VH comprises the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL comprises the amino acid sequence of SEQ ID NO: 137.

[0140] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH comprises the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL comprises the amino acid sequence of SEQ ID NO: 63, and the above CD3-VH comprises the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL comprises the amino acid sequence of SEQ ID NO: 137.

[0141] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH comprises the amino acid sequence of SEQ ID NO: 91, and the above DLL3-VL comprises the amino acid sequence of SEQ ID NO: 87, and the above CD3-VH comprises the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL comprises the amino acid sequence of SEQ ID NO: 137.

[0142] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 77. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0143] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0144] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 87. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0145] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, the above linker 3 and linker 4 are both peptide linkers known in the art as long as the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker may be a flexible peptide having 1 to 50 or 3 to 20 amino acid residues. In some embodiments, the length of the above peptide linker is 3 to 15 amino acid residues. In some embodiments, the above peptide linkers 3 and 4 each independently have the structure of (GGGGS)n, where n is 1 to 5. In some embodiments, n is 1, 2, 3, or 4. In some embodiments, the sequence of the above linker 3 is GGGGSGGGGSGGGGS (SEQ ID NO: 148). In some embodiments, the sequence of the above linker 4 is GGGGS (SEQ ID NO: 147).

[0146] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the CH1 is the CH1 sequence of IgG. In some embodiments, the CH1 is the CH1 of IgG1. In some embodiments, the CH1 comprises the amino acid sequence of SEQ ID NO: 141.

[0147] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the CL is the constant region of the light chain of an antibody. In some embodiments, the antigen-binding molecule according to any one of the above, wherein the CL is the constant region of the kappa chain or the lambda chain of the light chain. In some embodiments, the CL comprises the amino acid sequence of SEQ ID NO: 142.

[0148] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule one first chain comprising the amino acid sequence of SEQ ID NO: 173, one second chain comprising the amino acid sequence of SEQ ID NO: 174, and one third chain comprising the amino acid sequence of SEQ ID NO: 160, or one first chain comprising the amino acid sequence of SEQ ID NO: 173, one second chain comprising the amino acid sequence of SEQ ID NO: 174, and one third chain comprising the amino acid sequence of SEQ ID NO: 159, or one first chain comprising the amino acid sequence of SEQ ID NO: 157, one second chain comprising the amino acid sequence of SEQ ID NO: 158, and one third chain comprising the amino acid sequence of SEQ ID NO: 159, or one first chain comprising the amino acid sequence of SEQ ID NO: 157, one second chain comprising the amino acid sequence of SEQ ID NO: 158, and one third chain comprising the amino acid sequence of SEQ ID NO: 160, or one first chain comprising the amino acid sequence of SEQ ID NO: 166, one second chain comprising the amino acid sequence of SEQ ID NO: 167, and one third chain comprising the amino acid sequence of SEQ ID NO: 159, or One first chain comprising the amino acid sequence of SEQ ID NO: 166, one second chain comprising the amino acid sequence of SEQ ID NO: 167, one third chain comprising the amino acid sequence of SEQ ID NO: 160, or One first chain comprising the amino acid sequence of SEQ ID NO: 180, one second chain comprising the amino acid sequence of SEQ ID NO: 181, one third chain comprising the amino acid sequence of SEQ ID NO: 159, or It has one first chain comprising the amino acid sequence of SEQ ID NO: 180, one second chain comprising the amino acid sequence of SEQ ID NO: 181, and one third chain comprising the amino acid sequence of SEQ ID NO: 160.

[0149] In some embodiments, it is the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule has one first chain comprising the amino acid sequence of SEQ ID NO: 173, one second chain comprising the amino acid sequence of SEQ ID NO: 174, and one third chain comprising the amino acid sequence of SEQ ID NO: 160.

[0150] In some embodiments, it is the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3. The antigen-binding molecule comprises one first chain having a structure represented by formula (h) and one second chain having a structure represented by formula (i). (h) [DLL3-VL]-[Linker 5]-[CD3-VH]-[Linker 6]-[Fc1] / [Fc1], and (i) [CD3-VL]-[Linker 7]-[DLL3-VH]-[Linker 8]-[Fc2] / [Fc2], wherein the Linker 5, Linker 6, Linker 7 and Linker 8 are the same or different peptide linkers. The structures represented by formula (h) and (i) are arranged in sequence from the N-terminus to the C-terminus. " / " indicates "or", that is, Fc1 and Fc2 may be interchanged in position.

[0151] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3. The antigen-binding molecule comprises one first chain having a structure represented by formula (h) and one second chain having a structure represented by formula (i). (h) [DLL3-VL]-[Linker 5]-[CD3-VH]-[Linker 6]-[Fc1], and (i) [CD3-VL]-[Linker 7]-[DLL3-VH]-[Linker 8]-[Fc2], wherein the Linker 5, Linker 6, Linker 7, and Linker 8 are the same or different peptide linkers. The structures represented by formula (h) and (i) are arranged from the N-terminus to the C-terminus, and Fc1 and Fc2 may be interchanged in position.

[0152] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3. The antigen-binding molecule comprises one first chain having a structure represented by formula (h) and one second chain having a structure represented by formula (i). (h) [DLL3-VL]-[Linker 5]-[CD3-VH]-[Linker 6]-[Fc1], and (i) [CD3-VL]-[Linker 7]-[DLL3-VH]-[Linker 8]-[Fc2], wherein the Linker 5, Linker 6, Linker 7, and Linker 8 are the same or different peptide linkers. The structures represented by formula (h) and (i) are arranged from the N-terminus to the C-terminus.

[0153] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3. The antigen-binding molecule comprises one first chain having a structure represented by formula (h') and one second chain having a structure represented by formula (i'). (h') [CD3-VL] - [Linker 5] - [DLL3-VH] - [Linker 6] - [Fc1] / [Fc2], and (I') [DLL3-VL] - [Linker 7] - [CD3-VH] - [Linker 8] - [Fc2] / [Fc1], where the Linker 5, Linker 6, Linker 7, and Linker 8 are the same or different peptide linkers. The structures represented by formula (h') and (i') are arranged from the N-terminus to the C-terminus. " / " indicates "or".

[0154] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3. The antigen-binding molecule comprises one first chain having a structure represented by formula (h') and one second chain having a structure represented by formula (i'). (h') [CD3-VL] - [Linker 5] - [DLL3-VH] - [Linker 6] - [Fc1], and (I') [DLL3-VL] - [Linker 7] - [CD3-VH] - [Linker 8] - [Fc2], where the Linker 5, Linker 6, Linker 7, and Linker 8 are the same or different peptide linkers. The structures represented by formula (h') and (i') are arranged from the N-terminus to the C-terminus, and Fc1 and Fc2 may be interchanged in position.

[0155] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3, the antigen-binding molecule comprises one first chain having a structure represented by formula (h') and one second chain having a structure represented by formula (i'), (h') [CD3-VL]-[Linker 5]-[DLL3-VH]-[Linker 6]-[Fc1], and (I') [DLL3-VL]-[Linker 7]-[CD3-VH]-[Linker 8]-[Fc2], wherein the Linker 5, Linker 6, Linker 7 and Linker 8 are the same or different peptide linkers, the structures represented by formula (h') and (i') are arranged in the order from the N-terminus to the C-terminus.

[0156] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the DLL3-VH has DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL has DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 25, and the CD3-VH has CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131 or 135, and the CD3-VL has CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0157] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 25, and the above CD3-VH has a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0158] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 72, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 25, and the above CD3-VH has a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0159] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 74, and the CD3-VH has a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131 or 135, and the CD3-VL has a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0160] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 74, and The above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0161] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, and The above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0162] In some embodiments, it is an antigen-binding molecule according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, and The above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0163] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, and The above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0164] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, and the above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0165] In some embodiments, the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, and the above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0166] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 33, and the DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 36, and the CD3-VH has a CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 131 or 135, and the CD3-VL has a CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 134.

[0167] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 119, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and the DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 40, and The above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131 or 135, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0168] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, and The above CD3-VH has a CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, a CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and a CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: x35, and the above CD3-VL has a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0169] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, and It should be noted that in the translation of the CD3-HCDR3 in item , there is an "x" in "SEQ ID NO: x35" in the original text which may be an error. I translated it as is according to the rules. If this is a real error, it needs to be corrected in the original text for a more accurate translation. The above CD3-VH has CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131, and the above CD3-VL has CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134.

[0170] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 61. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0171] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0172] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 64. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0173] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 65. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0174] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 66. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0175] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 67. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0176] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 65. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0177] In some embodiments, it is the antigen-binding molecule described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 66. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0178] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, and the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0179] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 87, and the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0180] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 77, and the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0181] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100, and the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137.

[0182] In some embodiments, it is the antigen-binding molecule according to any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63. Also, the above CD3-VH contains the amino acid sequence of SEQ ID NO: 136, and the above CD3-VL contains the amino acid sequence of SEQ ID NO: 137. In some embodiments, the antigen-binding molecule according to any one of the above, wherein the linker 5, linker 6, linker 7, and linker 8 are all peptide linkers known in the art as long as the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker may be a flexible peptide containing 1 to 50 or 3 to 20 amino acid residues. In some embodiments, the length of the peptide linker is 1 to 15 amino acid residues. In some embodiments, the linker 5 has a structure of (GGGS)nGm, wherein n is 1 to 5, preferably 1, 2, or 3, and m is 1 to 10, preferably 4, 5, 6, 7, or 8. In some embodiments, the sequence of the linker 5 is GGGSGGGG (SEQ ID NO: 149). In some embodiments, the linkers linker 6 and linker 8 have a structure of Gm, wherein m is 1 to 5, preferably 1, 2, or 3. In some embodiments, the sequences of linker 6 and linker 8 are G (SEQ ID NO: 150). In some embodiments, the linker 7 has a structure of (GGGGS)nGm, wherein n is 1 to 5, preferably 1, 2, or 3, and m is 1 to 10, preferably 4, 5, 6, 7, or 8. In some embodiments, the sequence of linker 7 is GGGGSGGGG (SEQ ID NO: 151).

[0183] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule One first chain containing the amino acid sequence of SEQ ID NO: 185, and one second chain containing the amino acid sequence of SEQ ID NO: 162, or One first chain containing the amino acid sequence of SEQ ID NO: 161, and one second chain containing the amino acid sequence of SEQ ID NO: 162, or One first strand comprising the amino acid sequence of SEQ ID NO: 163, one second strand comprising the amino acid sequence of SEQ ID NO: 162, or One first strand comprising the amino acid sequence of SEQ ID NO: 259, one second strand comprising the amino acid sequence of SEQ ID NO: 162, or One first strand comprising the amino acid sequence of SEQ ID NO: 260, one second strand comprising the amino acid sequence of SEQ ID NO: 162, or One first strand comprising the amino acid sequence of SEQ ID NO: 168, one second strand comprising the amino acid sequence of SEQ ID NO: 169, or One first strand comprising the amino acid sequence of SEQ ID NO: 170, one second strand comprising the amino acid sequence of SEQ ID NO: 169, or One first strand comprising the amino acid sequence of SEQ ID NO: 175, one second strand comprising the amino acid sequence of SEQ ID NO: 176, or One first strand comprising the amino acid sequence of SEQ ID NO: 177, one second strand comprising the amino acid sequence of SEQ ID NO: 176, or One first strand comprising the amino acid sequence of SEQ ID NO: 182, one second strand comprising the amino acid sequence of SEQ ID NO: 183, or One first strand comprising the amino acid sequence of SEQ ID NO: 184, one second strand comprising the amino acid sequence of SEQ ID NO: 183, or One first strand comprising the amino acid sequence of SEQ ID NO: 186, one second strand comprising the amino acid sequence of SEQ ID NO: 162, or One first strand comprising the amino acid sequence of SEQ ID NO: 187, one second strand comprising the amino acid sequence of SEQ ID NO: 188, or One first strand comprising the amino acid sequence of SEQ ID NO: 187, one second strand comprising the amino acid sequence of SEQ ID NO: 189, or One first strand comprising the amino acid sequence of SEQ ID NO: 190, one second strand comprising the amino acid sequence of SEQ ID NO: 188, or One first strand comprising the amino acid sequence of SEQ ID NO: 190, one second strand comprising the amino acid sequence of SEQ ID NO: 189, or One first strand comprising the amino acid sequence of SEQ ID NO: 191, one second strand comprising the amino acid sequence of SEQ ID NO: 188, or It has one first chain comprising the amino acid sequence of SEQ ID NO: 191 and one second chain comprising the amino acid sequence of SEQ ID NO: 189.

[0184] In some embodiments, it is the antigen-binding molecule according to any one of the above, wherein the antigen-binding molecule has one first chain comprising the amino acid sequence of SEQ ID NO: 185 and one second chain comprising the amino acid sequence of SEQ ID NO: 162.

[0185] In another aspect, the present disclosure further provides an anti-DLL3 antibody capable of specifically binding to DLL3, the anti-DLL3 antibody comprising a heavy chain variable region DLL3-VH and a light chain variable region DLL3-VL, wherein (i) DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in the DLL3-VH each comprise the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in SEQ ID NO: 12, 56 or 57, and DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in the DLL3-VL each comprise the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in SEQ ID NO: 13, 63, 64, 65, 66 or 67, or (ii) DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in the DLL3-VH each comprise the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in SEQ ID NO: 14, 79, 80, 81 or 82, and DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in the DLL3-VL each comprise the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in SEQ ID NO: 15, or (iii) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 16, 91, 92, 93, or 94, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 17, or (iv) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 18, 107, 108, 109, 110, 112, 113, 114, or 115, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 19.

[0186] In some embodiments, it is an anti-DLL3 antibody described in any one of the above, among which, (i) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 12, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 13, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 54, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 64, or DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 54, and DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 63, or DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 56, and DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 65, or DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 56, and DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 66, or DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 56, and DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 67, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 57, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 65, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 57, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 66, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 57, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 67, or (ii) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 14, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 15, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 81, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 77, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 79, 80, or 82, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 77, or (iii) The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 16, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 17, or The DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in the above DLL3-VH each contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2, and DLL3-HCDR3 in SEQ ID NO: 91, and the DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in the above DLL3-VL each contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 in SEQ ID NO: 87, or The DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in the above DLL3-VH contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in SEQ ID NO: 92, 93 or 94 respectively, and the DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in the above DLL3-VL contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in SEQ ID NO: 87 respectively, or (iv) The DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in the above DLL3-VH contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in SEQ ID NO: 18 respectively, and the DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in the above DLL3-VL contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in SEQ ID NO: 19 respectively, or The DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in the above DLL3-VH contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in SEQ ID NO: 109 respectively, and the DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in the above DLL3-VL contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in SEQ ID NO: 100 respectively, or The DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in the above DLL3-VH contain the amino acid sequences of DLL3-HCDR1, DLL3-HCDR2 and DLL3-HCDR3 in SEQ ID NO: 107, 108, 110, 112, 113, 114 or 115 respectively, and the DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in the above DLL3-VL contain the amino acid sequences of DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 in SEQ ID NO: 100 respectively.

[0187] In some embodiments, the DLL3-HCDR1, DLL3-HCDR2, DLL3-HCDR3, DLL3-LCDR1, DLL3-LCDR2, and DLL3-LCDR3 are defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering rules.

[0188] In some embodiments, it is the anti-DLL3 antibody according to any one of the above, among which, the DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, the DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or the DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or ii) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26 or 84, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27 or 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 28 or 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or iii) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 32, 96, 97, 98 or 99, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, or iv) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 37, 117, 118, 119 or 120, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40.

[0189] In some embodiments, it is an anti-DLL3 antibody according to any one of the above, among which, i) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74.

[0190] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, i) The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or ii) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 28, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or iii) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, or iv) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40.

[0191] In some embodiments, it is an anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25.

[0192] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25.

[0193] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31.

[0194] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36.

[0195] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40.

[0196] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, wherein the DLL3-HCDR1, DLL3-HCDR2, DLL3-HCDR3, DLL3-LCDR1, DLL3-LCDR2 and DLL3-LCDR3 are defined according to the Kabat numbering rule.

[0197] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, which has a [concentration value] at 25 °C of 4×10 -9 M, 3×10 -9 M, 2×10 -9 M, 1×10 -9 M, 9×10 -10 M, 8×10 -10 M, 7×10 -10 M, 6×10 -10 M, 5×10 -10 M, 4×10 -10 M, 3×10 -10 M, 2×10 -10 M, 1×10 -10 M, 9×10 It should be noted that there seems to be some missing or incorrect information in the original text around line where the concentration values are presented in an incomplete and perhaps incorrect way. The translation is done based on the existing text as accurately as possible.-11 Binds to human DLL3 with a KD of less than M, where the KD is measured by surface plasmon resonance.

[0198] In some embodiments, the anti-DLL3 antibody described above, among which, (i) The DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the FR region of the DLL3-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A, and The DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, 71, 72 or 73, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 25 or 74, and the FR region of the DLL3-VL comprises one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or (ii) The DLL3-VH has a DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 26 or 84, a DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 27 or 85, and a DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 28 or 83, and The DLL3-VL has a DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 31, and the FR region of the DLL3-VL comprises one or more amino acid substitutions selected from the group consisting of 42G, 44V and 71Y, or (iii) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 32, 96, 97, 98 or 99, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 24T, 44S, 71V and 73K, and The above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 9K, 43S, 68A and 85D, or (iv) The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 37, 117, 118, 119 or 120, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 3R, 5Q, 7F, 9P, 10V, 12V, 40S, 41H, 44S, 48I, 67A, 69L, 71V, 73K, 75S and 83T, and The above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 9K, 43S, 60D, 68A, 87H and 100S.

[0199] In some embodiments, it is the antigen-binding molecule described in any one of the above, which is 4×10 -9 M, 3×10 -9 M, 2×10 -9 M, 1×10 -9 M, 9×10 -10 M, 8×10 -10 M, 7×10 -10M, 6×10 -10 M, 5×10 -10 M, 4×10 -10 M, 3×10 -10 M, 2×10 -10 M, 1×y10 -10 M, 9×10 -11 Bind to human DLL3 with a KD less than M, where the KD is measured by surface plasmon resonance method.

[0200] In some embodiments, it is an anti-DLL3 antibody according to any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. The FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. The FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. The FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. The FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q and 85D.

[0201] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D.

[0202] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y, or The above DLL3-VH has DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the above DLL3-VL has DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y, or The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 28, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31. Also, the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 42G, 44V, and 71Y.

[0203] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 24T, 44S, 71V, and 73K, and the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36. And the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 1N, 9K, 43S, 68A, and 85D.

[0204] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH has a DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, a DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and a DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38. Also, the FR region of the above DLL3-VH contains one or more amino acid substitutions selected from the group consisting of 1E, 3R, 5Q, 7F, 9P, 10V, 12V, 40S, 41H, 44S, 48I, 67A, 69L, 71V, 73K, 75S, and 83T. And the above DLL3-VL has a DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, a DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and a DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40. And the FR region of the above DLL3-VL contains one or more amino acid substitutions selected from the group consisting of 9K, 43S, 60D, 68A, 87H, and 100S.

[0205] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 50 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of Q1E, Q43K, M48I, V67A, I69L, R71V, T73K, and S76N in the FR region of SEQ ID NO: 50.

[0206] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 51 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of Q1E, 5Q, R38K, V68A, F69L, L71V, T73K, V75S, and S76N in the FR region of SEQ ID NO: 51.

[0207] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 52 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of F27Y, S30T, I69L, R71V, D73K, and T93A in the FR region of SEQ ID NO: 52.

[0208] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 62 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of F36L, A43S, P44F, S46G, T69A, F71Y, and T85D in the FR region of SEQ ID NO: 62.

[0209] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 68 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of Y36L, Q42K, L46G, T69A, F71Y, E79Q, and V85D in the FR region of SEQ ID NO: 68.

[0210] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 78 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 78.

[0211] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 75 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of K42G, P44V, and F71Y in the FR region of SEQ ID NO: 75.

[0212] In some embodiments, the anti-DLL3 antibody described in any one of the above, among which, the above DLL3-VH comprises the amino acid sequence of SEQ ID NO: 95 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of Q1E, A24T, R44S, R71V, and T73K in the FR region of SEQ ID NO: 95.

[0213] In some embodiments, the anti-DLL3 antibody described in any one of the above, among which, the above DLL3-VL comprises the amino acid sequence of SEQ ID NO: 88 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of D1N, D9K, P43S, G68A, and V85D in the FR region of SEQ ID NO: 88.

[0214] In some embodiments, the anti-DLL3 antibody described in any one of the above, among which, the above DLL3-VH comprises the amino acid sequence of SEQ ID NO: 116 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of Q1E, Q3R, V5Q, S7F, A9P, E10V, K12V, A40S, P41H, R44S, M48I, V67A, I69L, R71V, T73K, A75S, and R83T in the FR region of SEQ ID NO: 116.

[0215] In some embodiments, the anti-DLL3 antibody described in any one of the above, among which, the above DLL3-VL comprises the amino acid sequence of SEQ ID NO: 100 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of D9K, P43S, G68A, and Y87H in the FR region of SEQ ID NO: 100.

[0216] In some embodiments, the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 103 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of A43S, S60D, and Q100S in the FR region of SEQ ID NO: 103.

[0217] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 56.

[0218] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 57.

[0219] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 63, and in some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of A43S and P44F.

[0220] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 64 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions in the FR region of SEQ ID NO: 64, and in some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of A43S and P44F.

[0221] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VL comprises the amino acid sequence of SEQ ID NO: 65 or a variant thereof. In some embodiments, the above variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 65, and in some embodiments, the above amino acid substitution is one or more amino acid substitutions selected from the group consisting of A43S and P44F.

[0222] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VL comprises the amino acid sequence of SEQ ID NO: 66 or a variant thereof. In some embodiments, the above variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 66, and in some embodiments, the above amino acid substitution is one or more amino acid substitutions selected from the group consisting of A43S and P44F.

[0223] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VL comprises the amino acid sequence of SEQ ID NO: 67 or a variant thereof. In some embodiments, the above variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 67.

[0224] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VH comprises the amino acid sequence of SEQ ID NO: 79, 80, 81 or 82, or a variant of SEQ ID NO: 79, 80, 81 or 82. In some embodiments, the above variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 79, 80, 81 or 82, and the above DLL3-VL comprises the amino acid sequence of SEQ ID NO: 75 or a variant thereof. In some embodiments, the above variant comprises one or more amino acid substitutions selected from the group consisting of K42G, P44V and F71Y in the FR region of SEQ ID NO: 75.

[0225] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the DLL3-VH includes the amino acid sequence of SEQ ID NO: 91, 92, 93 or 94, or a variant of the amino acid sequence of SEQ ID NO: 91, 92, 93 or 94. In some embodiments, the variant includes one or more amino acid substitutions in the FR region of SEQ ID NO: 91, 92, 93 or 94, and the DLL3-VL includes the amino acid sequence of SEQ ID NO: 88 or a variant thereof. In some embodiments, the variant includes one or more amino acid substitutions selected from the group consisting of D1N, D9K, P43S, G68A and V85D in the FR region of SEQ ID NO: 88.

[0226] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the DLL3-VH includes the amino acid sequence of SEQ ID NO: 107, 108, 109 or 110, or a variant of the amino acid sequence of SEQ ID NO: 107, 108, 109 or 110. In some embodiments, the variant includes one or more amino acid substitutions in the FR region of SEQ ID NO: 107, 108, 109 or 110. In some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of V5Q, S7F, A9P, E10V, K12V, A40S, P41H, M48I, V67A, A75S and R83T.

[0227] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the DLL3-VH includes the amino acid sequence of SEQ ID NO: 112, or a variant of the amino acid sequence of SEQ ID NO: 112. In some embodiments, the variant includes one or more amino acid substitutions in the FR region of SEQ ID NO: 112. In some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of V5Q, A9P, K12V, A40S, P41H, 4M8I, V67A and R83T.

[0228] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VH comprises the amino acid sequence of SEQ ID NO: 113, or a variant of SEQ ID NO: 113. In some embodiments, the variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 113. In some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of V5Q, S7F, A9P, E10V, K12V, A40S, P41H, A75S, and R83T.

[0229] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VH comprises the amino acid sequence of SEQ ID NO: 114, or a variant of SEQ ID NO: 114. In some embodiments, the variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 114. In some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of V5Q, S7F, A9P, E10V, K12V, M48I, V67A, A75S, and R83T.

[0230] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VH comprises the amino acid sequence of SEQ ID NO: 115, or a variant of SEQ ID NO: 115. In some embodiments, the variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 115. In some embodiments, the amino acid substitution is one or more amino acid substitutions selected from the group consisting of V5Q, A9P, K12V, A40S, P41H, M48I, and V67A.

[0231] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of D9K, P43S, G68A, and Y87H in the FR region of SEQ ID NO: 100.

[0232] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, The above DLL3-VL contains the amino acid sequence of SEQ ID NO: 103 or a variant thereof. In some embodiments, the variant contains one or more amino acid substitutions selected from the group consisting of A43S, S60D, and Q100S in the FR region of SEQ ID NO: 103.

[0233] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, i) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, or 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63, 64, 65, 66, or 67, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56 or 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, or 68, or ii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 78, 79, 80, 81, or 82, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 75, 76, or 77, or iii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 89, 90, 91, 92, 93, 94, or 95, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 86, 87, or 88, or iv) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, or 116, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100, 101, 102, 103, or 104.

[0234] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 43, 44 or 45, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 58, 59 or 60, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 47, 48, 49, 53, 54 or 55, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 59, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 43, 44 or 45, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 60, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 46, 48, 53, 54 or 55, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 61, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63 or 64, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56 or 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, 66 or 67.

[0235] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 78 or 79, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 75, 76 or 77, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 78, 79, 80, 81 or 82, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 77.

[0236] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 89, 90, 91, 92, 93 or 94, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 86 or 87, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 95, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 87.

[0237] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 105, 106, 107, 108, 109, 110 or 111, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100, 101 or 102, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 112, 113, 114 or 115, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100, 103 or 104, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 103.

[0238] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, i) the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 61, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 64, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, or the above DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, or The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, or ii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 77, or iii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 87, or iv) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 100.

[0239] In some embodiments, the anti-DLL3 antibody described above, among which, i) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 12, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 13, or ii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 14, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 15, or iii) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 16, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 17, or iv) The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 18, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 19.

[0240] In some embodiments, the anti-DLL3 antibody according to any one of the above, among which, The above DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above DLL3-VL contains the amino acid sequence of SEQ ID NO: 63, or The above-mentioned DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the above-mentioned DLL3-VL contains the amino acid sequence of SEQ ID NO: 61.

[0241] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, the above-mentioned DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the above-mentioned DLL3-VL contains the amino acid sequence of SEQ ID NO: 77.

[0242] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, the above-mentioned DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the above-mentioned DLL3-VL contains the amino acid sequence of SEQ ID NO: 87.

[0243] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, the above-mentioned DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the above-mentioned DLL3-VL contains the amino acid sequence of SEQ ID NO: 100.

[0244] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, the anti-DLL3 antibody is an antibody fragment.

[0245] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, the antibody fragment is Fab, Fab’, F(ab’)2, Fd, Fv, scFv, dsFv or dAb.

[0246] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, the anti-DLL3 antibody contains a heavy chain constant region and a light chain constant region.

[0247] In some embodiments, it is the anti-DLL3 antibody described in any one of the above, among which, the heavy chain constant region is the heavy chain constant region of human IgG.

[0248] In some embodiments, the anti-DLL3 antibody according to any one of the above, wherein the light chain constant region is a human κ or λ light chain constant region.

[0249] In some embodiments, the anti-DLL3 antibody according to any one of the above, wherein the heavy chain constant region is a human IgG1 heavy chain constant region.

[0250] In some embodiments, the anti-DLL3 antibody according to any one of the above, wherein the light chain constant region is a human κ light chain constant region.

[0251] In some embodiments, the anti-DLL3 antibody according to any one of the above, wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 41.

[0252] In some embodiments, the anti-DLL3 antibody according to any one of the above, wherein the light chain constant region comprises the amino acid sequence of SEQ ID NO: 42.

[0253] In some embodiments, the anti-DLL3 antibody according to any one of the above, wherein the anti-DLL3 antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with SEQ ID NO: 121, and the light chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with SEQ ID NO: 122, or The heavy chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with SEQ ID NO: 123, and the light chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with SEQ ID NO: 124, or The heavy chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with SEQ ID NO: 125, and the light chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with SEQ ID NO: 126, or The heavy chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with SEQ ID NO: 127, and the light chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity with SEQ ID NO: 128.

[0254] In some embodiments, the anti-DLL3 antibody according to any one of the above, wherein the anti-DLL3 antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 121, and the light chain comprises the amino acid sequence of SEQ ID NO: 122, or the heavy chain comprises the amino acid sequence of SEQ ID NO: 123, and the light chain comprises the amino acid sequence of SEQ ID NO: 124, the heavy chain comprises the amino acid sequence of SEQ ID NO: 125, and the light chain comprises the amino acid sequence of SEQ ID NO: 126, or the heavy chain comprises the amino acid sequence of SEQ ID NO: 127, and the light chain comprises the amino acid sequence of SEQ ID NO: 128.

[0255] In some embodiments, it is the anti-DLL3 antibody according to any one of the above, wherein the anti-DLL3 antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 121, and the light chain comprises the amino acid sequence of SEQ ID NO: 122.

[0256] In some embodiments, it is the anti-DLL3 antibody according to any one of the above, wherein the anti-DLL3 antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 125, and the light chain comprises the amino acid sequence of SEQ ID NO: 126.

[0257] In some embodiments, it is the anti-DLL3 antibody according to any one of the above, wherein the anti-DLL3 antibody is a bispecific antibody.

[0258] In some embodiments, it is the anti-DLL3 antibody according to any one of the above, wherein the anti-DLL3 antibody is a bispecific antibody, and the bispecific antibody specifically binds to DLL3 and CD3.

[0259] In another aspect, the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of the antigen-binding molecule according to any one of the above or the anti-DLL3 antibody according to any one of the above, and one or more pharmaceutically acceptable carriers, diluents, buffers or excipients. In some embodiments, the pharmaceutical composition further comprises at least one second therapeutic agent. In one example, the second therapeutic agent is any agent that is preferably combined with a CD3 / DLL3 bispecific antigen-binding molecule. In some embodiments, the second therapeutic agent is an antibody that can specifically bind to CD28. In some embodiments, the second therapeutic agent is a bispecific antibody that can specifically bind to CD28 and a tumor cell surface antigen (TAA). In some embodiments, the second therapeutic agent is a bispecific antibody that can specifically bind to CD28 and DLL3.

[0260] In another aspect, the present disclosure further provides an isolated nucleic acid encoding the antigen-binding molecule described in any one of the above or the anti-DLL3 antibody described in any one of the above.

[0261] In another aspect, the present disclosure further provides a vector comprising the isolated nucleic acid.

[0262] In another aspect, the present disclosure further provides a host cell comprising the isolated nucleic acid or vector.

[0263] In another aspect, the present disclosure further provides a method for treating a tumor or cancer, the method comprising administering to a subject a therapeutically effective amount of the antigen-binding molecule described in any one of the above or the anti-DLL3 antibody described in any one of the above or the pharmaceutical composition described in any one of the above.

[0264] In another aspect, the present disclosure further provides the use of the antigen-binding molecule described in any one of the above or the antibody described in any one of the above or the pharmaceutical composition described in any one of the above in the preparation of a medicament for treating a tumor or cancer.

[0265] In another aspect, the present disclosure further provides the antigen-binding molecule described in any one of the above or the anti-DLL3 antibody described in any one of the above or the pharmaceutical composition described in any one of the above for use as a medicament. In some embodiments, the medicament is used for treating a tumor or cancer.

[0266] In some embodiments, the tumor or cancer described in any one of the above is selected from head and neck squamous cell carcinoma, head and neck cancer, brain cancer, glioma, glioblastoma multiforme, neuroblastoma, central nervous system cancer, neuroendocrine tumor, pharyngeal cancer, pharyngeal squamous cell carcinoma, oral squamous cell carcinoma, nasopharyngeal cancer, esophageal cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer, liver cancer, hepatobiliary cystic cancer, pancreatic cancer, gastric cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, kidney cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, large cell lung cancer, triple negative breast cancer, lymphoma, and small cell lung cancer.

[0267] In some embodiments, the above-mentioned tumor or cancer is a cancer that expresses DLL3.

[0268] In some embodiments, the above-mentioned tumor or cancer is a solid tumor.

[0269] In some embodiments, the above-mentioned tumor or cancer is lung cancer.

[0270] In some embodiments, the above-mentioned tumor or cancer is small cell lung cancer.

[0271] In some embodiments, a method for treating the above-mentioned tumor or cancer, which further comprises using a second therapeutic agent. In some embodiments, the second therapeutic agent includes an anti-tumor agent, radiotherapy, an antibody-drug conjugate, a bispecific antibody, a bispecific antibody conjugated with an anti-tumor agent, an immune checkpoint inhibitor, or a combination thereof. [[ID=!8]]

[0272] In some embodiments, a method for treating the above-mentioned tumor or cancer, wherein the second therapeutic agent is any agent that is preferably combined with a CD3 / DLL3 bispecific antigen-binding molecule. In some embodiments, the second therapeutic agent is an antibody that can specifically bind to CD28. In some embodiments, the second therapeutic agent is a bispecific antibody that can specifically bind to both CD28 and a tumor cell surface antigen (TAA). In some embodiments, the second therapeutic agent is a bispecific antibody that can specifically bind to both CD28 and DLL3.

[0273] In some embodiments, a method for treating the above-mentioned tumor or cancer, wherein the second therapeutic agent is administered simultaneously, sequentially, or separately from the antigen-binding molecule described in any one of the present disclosure.

[0274] The antigen-binding molecules provided in the present disclosure have good characteristics such as therapeutic activity, safety, pharmacokinetic properties, and drug development potential (e.g., stability). BRIEF DESCRIPTION OF THE DRAWINGS

[0275]

Figure 1A

Figure 1B

Figure 1C

Figure 2A

Figure 2B

Figure 3

Figure 4A

Figure 4B

Figure 5A

Figure 5B

Modes for Carrying Out the Invention

[0276] Term The terms used in this specification are for the purpose of merely describing embodiments and are not intended for limitation. Unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by those skilled in the art.

[0277] Unless otherwise specifically stated in the context, throughout the specification and claims, words such as "comprising", "having", "containing", etc. should be understood in an inclusive sense rather than an exclusive or exhaustive sense, that is, in the sense of "including but not limited to". Unless otherwise specified, "comprising" includes "consisting of". For example, in the case of DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, it clearly covers DLL3-HCDR1 whose amino acid sequence is shown by SEQ ID NO: 20.

[0278] The three-letter codes and one-letter codes of amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).

[0279] The term "and / or", for example, "X and / or Y", should be understood to mean "X and Y" or "X or Y", and should be used to provide clear support for both meanings or either one of the meanings.

[0280] Unless otherwise specified as being derived from non-human species (e.g., "mouse CD3", "mouse CD3 fragment", "monkey CD3", "monkey CD3 fragment", etc.), "CD3" and "CD3 fragment" as used in this specification refer to the well-known human CD3 protein or fragments thereof.

[0281] The term "amino acid" refers to naturally occurring amino acids, synthetic amino acids, and amino acid analogs and mimetics that act in the same manner as naturally occurring amino acids. Naturally occurring amino acids include those that are encoded by codons and those that are subsequently modified, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., an α-carbon bonded to a hydrogen, a carboxy group, an amino group, and an R group), such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have a modified R group (e.g., norleucine) or a modified peptide backbone but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to chemical compounds that have a structure different from the general chemical structure of amino acids but act in the same manner as naturally occurring amino acids.

[0282] The term "amino acid mutation" includes amino acid substitution, deletion, insertion and modification. If the final construct has a desired property such as reducing binding to the Fc receptor, the final construct can be achieved by performing any combination of substitutions, deletions, insertions and modifications. Deletions and insertions of amino acid sequences include deletions and insertions at the amino terminus and / or carboxy terminus of the polypeptide chain. Specific amino acid mutations may be amino acid substitutions. In one embodiment, the amino acid mutation is a non-conservative amino acid substitution, i.e., one amino acid is replaced with another amino acid having different structural and / or chemical properties. Amino acid substitutions include replacement with non-natural amino acids or derivatives of the 20 natural amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated by genetic or chemical methods known in the art. Genetic methods may include site-directed mutagenesis, PCR, gene synthesis, etc. Methods for modifying amino acid side chain groups other than genetic engineering, such as chemical modification, are also expected to be available. In this specification, the same amino acid mutation can be indicated by various names. In this specification, the amino acid residue at a specific site can be indicated by the method of position + amino acid residue. For example, 366W indicates that the amino acid residue at the 366th site is W. T366W indicates that the amino acid residue at the 366th site has mutated from the original T to W.

[0283] The term "antigen-binding molecule" is used in the broadest sense if it exhibits the desired antigen-binding activity, covering various molecules that specifically bind to an antigen, including, but not limited to, antibodies, other polypeptides having antigen-binding activity, and antibody fusion proteins formed by fusing the two. The antigen-binding molecules herein include variable regions (VH) and variable regions (VL) that together constitute an antigen-binding domain. Exemplarily, the antigen-binding molecules herein are bispecific antigen-binding molecules (e.g., bispecific antibodies).

[0284] The term "antibody" is used in the broadest sense if it exhibits the desired antigen-binding activity and covers various antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antibody fragments (or antigen-binding fragments, or antibody fragments, or antigen-binding portions). From the context, one of ordinary skill in the art can determine the specific meaning that "antibody" refers to.

[0285] A "natural antibody" is an immunoglobulin molecule that exists naturally. For example, a natural IgG antibody is a heterotetrameric glycoprotein of approximately 150,000 daltons, composed of two light chains and two heavy chains linked by disulfide bonds. From the N-terminus to the C-terminus, each heavy chain has one variable region (VH, also called variable heavy chain domain or heavy chain variable region), followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has one variable region (VL, also called variable light chain domain or light chain variable domain), followed by one constant light chain domain (constant light chain region, CL). The terms "full-length antibody", "complete antibody", and "whole antibody" may be used interchangeably herein and refer to an antibody having a structure substantially similar to that of a natural antibody or having a heavy chain that includes an Fc region as defined herein.

[0286] The term "bispecific antibody" refers to an antibody (including an antibody or its antigen-binding fragment, such as a single-chain antibody) that can specifically bind to two different antigens or at least two different antigen epitopes of the same antigen. In the prior art, bispecific antibodies with various structures have been disclosed, and depending on the integrity of the IgG molecule, they can be divided into IgG-like bispecific antibodies and antibody fragment-type bispecific antibodies, and depending on the number of antigen-binding domains, they can be divided into bivalent, trivalent, tetravalent or higher polyvalent bispecific antibodies, and depending on whether the structure is symmetric, they can be divided into bispecific antibodies with a symmetric structure and bispecific antibodies with an asymmetric structure.Among them, bispecific antibodies based on antibody fragments are, for example, Fab fragments lacking the Fc fragment, and bispecific antibodies are formed by binding two or more Fab fragments to one molecule. They have relatively low immunogenicity, a small molecular weight, and high tumor tissue penetrability. Typical antibody structures of this type are bispecific antibodies such as F(ab)2, scFv-Fab, (scFv)2-Fab, etc. Antibodies such as IgG-like bispecific antibodies (for example, those having an Fc fragment) have a relatively large molecular weight. The Fc fragment contributes to the late purification of the antibody and improves its solubility and stability. The Fc portion can also bind to the receptor FcRn to increase the half-life of the antibody in the serum. Typical structural models of bispecific antibodies are, for example, KiH, CrossMAb, Triomab quadroma, FcΔAdp, ART-Ig, BiMAb, Biclonics, BEAT, DuoBody, Azymetric, XmAb, 2:1 TCBs, 1Fab-IgG TDB, FynomAb, two-in-one / DAF, scFv-Fab-IgG, DART-Fc, LP-DART, CODV-Fab-TL, HLE-BiTE, F(ab)2-CrossMAb, IgG-(scFv)2, Bs4Ab, DVD-Ig, Tetravalent-DART-Fc, (scFv)4-Fc, CODV-Ig, mAb2, F(ab)4-CrossMAb, etc. (see Aran F. Labrijn et al., Nature Reviews Drug Discovery volume 18, pages 585 - 608 (2019), Chen S1 et al., J Immunol Res. 2019 Feb 11, 2019:4516041).

[0287] The term "variable region" or "variable domain" refers to the domain in an antigen-binding molecule that binds to an antigen. In this specification, an antigen-binding module that specifically binds to CD3 has its heavy-chain variable region designated as CD3-VH and its light-chain variable region designated as CD3-VL. The VH and VL each contain four conserved framework regions (FRs) and three complementarity-determining regions (CDRs). Among them, the term "complementarity-determining region" or "CDR" refers to the region that mainly promotes the binding to the antigen in the variable domain, and the "framework" or "FR" refers to the variable domain residues excluding the CDR residues. VH contains three CDR regions designated as HCDR1, HCDR2, and HCDR3, and VL contains three CDR regions designated as LCDR1, LCDR2, and LCDR3. In this specification, the three CDR regions in CD3-VH are respectively designated as CD3-HCDR1, CD3-HCDR2, and CD3-HCDR3, and the three CDR regions in CD3-VL are respectively designated as CD3-LCDR1, CD3-LCDR2, and CD3-LCDR3. Each VH and VL is, in order from the N-terminus to the C-terminus, FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. A single VH or VL is capable of sufficiently conferring antigen-binding specificity.

[0288] The amino acid sequence boundaries of CDRs can be determined by various known methods such as, for example, the "Kabat" numbering rule (see Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD), the "Chothia" numbering rule, the "ABM" numbering rule, the "contact" numbering rule (see Martin, A.C.R. Protein Sequence and Structure Analysis of Antibody Variable Domains[J].2001), and the ImMunoGenTics (IMGT) numbering rule (Lefranc, M.P. et al., Dev.Comp.Immunol., 27, 55-77 (2003), Front Immunol. 2018 Oct 16;9:2278). The correspondence relationships between various numbering systems are well known to those skilled in the art. The numbering rule of the present disclosure is as shown in Table 1 below.

[0289] [Table 1] Unless otherwise specified, the variable regions and CDR sequences in the embodiments of the present disclosure all apply the "Kabat" numbering rule.

[0290] The term "antibody fragment" or "antigen-binding fragment" refers to a molecule different from a full antibody, which includes a part of a full antibody that retains the antigen-binding ability of the full antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab′)2, single-domain antibodies, single-chain Fab (scFab), diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and multispecific antibodies composed of antibody fragments.

[0291] The term "Fc region" or "fragment crystallizable region" is used to define the C-terminal region of an antibody heavy chain and includes both native Fc regions and modified Fc regions. In some embodiments, the Fc region comprises two subunits that are the same or different. In some embodiments, the Fc region of a human IgG heavy chain is defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxy terminus. Suitable native sequence Fc regions for use in the antibodies described herein include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4. Unless otherwise specified, the numbering convention for the Fc region is the EU index.

[0292] The term "Titin chain" refers to a peptide fragment containing the Titin Ig-Like 152 domain, which is 78-118 amino acids in length in the Titin protein, or a functional variant thereof, and the above Titin chain can bind to the Obscurin Ig-Like 1 or Obscurin-Like Ig-Like 1 domain to form a dimerization complex.

[0293] The term "Obscurin chain" refers to a peptide fragment containing the Obscurin Ig-Like 1 domain, which is 87-117 amino acids in length in the Obscurin protein, or a functional variant thereof, or a peptide fragment containing the Obscurin-Like Ig-Like 1 domain, which is 78-118 amino acids in length in the Obscurin-Like 1 protein, or a functional variant thereof.

[0294] The above Obscurin chain can bind to the Titin chain to form a dimerization complex. The Titin chain and Obscurin chain of the present disclosure can be used to replace CH1 and CL in Fab, respectively, to form a substituted Fab (Fab-S), and such substitution does not affect the binding of the antigen-binding molecule to the antigen.

[0295] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chains is derived from a particular origin or species, while the remaining portions of the heavy and / or light chains are derived from a different origin or species.

[0296] The term "humanized" antibody refers to an antibody that retains the reactivity of a non-human antibody while having relatively low immunogenicity in humans. For example, it may be achieved by retaining the non-human CDR regions and replacing the remaining portions of the antibody with their human counterparts (i.e., the constant region and the framework region portions of the variable region).

[0297] The term "affinity" refers to the total strength of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding ligand (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding affinity and reflects the 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its ligand Y can usually be expressed by the equilibrium dissociation constant (KD). Affinity can be measured by conventional methods known in the art (such as those described herein). The terms "kassoc" or "ka" refer to the association rate of a particular antibody-antigen interaction, and the terms "kdis" or "kd" as used herein refer to the dissociation rate of a particular antibody-antigen interaction. As used herein, the term "KD" refers to the equilibrium dissociation constant, which is obtained from the ratio of kd to ka (i.e., kd / ka) and is expressed in molar concentration (M). The KD value of an antibody can be measured by methods known in the art, such as surface plasmon resonance, ELISA, or solution equilibrium titration (SET).

[0298] The term "monoclonal antibody" basically refers to a population of antibodies that are homogeneous, i.e., the amino acid sequences of the antibody molecules contained in the population are the same except for minor natural variations that may exist. In contrast, polyclonal antibody preparations usually contain multiple different antibodies having different amino acid sequences that are specific for generally different epitopes in their variable domains. In some embodiments, the antibodies provided by the present disclosure are monoclonal antibodies.

[0299] The term "antigen" refers to a molecule or molecular moiety that can be bound by a selective binding agent of an antigen-binding molecule (e.g., an antibody). An antigen may have one or more epitopes that can interact with different antigen-binding molecules (e.g., antibodies).

[0300] The term "epitope" refers to a region (area or region) on an antigen that can specifically bind to an antibody or an antigen-binding fragment thereof. An epitope is formed from contiguous amino acids (linear epitope) or contains non-contiguous amino acids (conformational epitope), and for example, non-contiguous amino acids may be spatially brought close together by the folding of the antigen (i.e., by the tertiary folding of a proteinaceous antigen). Conformational epitopes and linear epitopes differ in that in the presence of a denaturing solvent, antibody binding to the conformational epitope is lost. An epitope contains at least 3, at least 4, at least 5, at least 6, at least 7, or 8 to 10 amino acids in a unique spatial conformation. Screening of antibodies that bind to a specific epitope (i.e., those that bind to the same epitope) can be performed by conventional methods in this field, for example, alanine scanning, peptide blotting (see Meth. Mol. Biol. 248 (2004) 443-463), peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of the antigen (see Prot. Sci. 9 (2000) 487-496), and cross-inhibition (see "Antibodies", Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., NY)), but is not limited thereto.

[0301] The terms "specifically bindable", "specifically binds" or "binds" refer to the ability of an antigen-binding molecule to bind to an antigen or epitope with a higher affinity compared to other antigens or epitopes. Generally, an antibody binds to an antigen or epitope with an equilibrium dissociation constant (KD) of about 1×10 -7 M or less (e.g., about 1×10 -8 M or less). In some embodiments, the KD for an antibody to bind to an antigen is 10% or less (e.g., 1%) of the KD for the antibody to bind to a non-specific antigen of the antibody (e.g., BSA, casein). The KD can be measured by known methods, e.g., measured by FACS or surface plasmon resonance assay. However, an antibody that specifically binds to an antigen or its epitope may have cross-reactivity with other related antigens, e.g., other species (homologs) (e.g., humans, or monkeys such as Macaca fascicularis (cynomolgus, cyno), Pan troglodytes (chimpanzee, chimp)) or cross-reactivity with the corresponding antigen from Callithrix jacchus (common marmoset, marmoset).

[0302] The term "does not bind" means that an antigen-binding molecule cannot bind to an antigen or its epitope in the above-described specific binding manner. For example, an antibody binds to an antigen or its epitope with an equilibrium dissociation constant (KD) of about 1×10 -6 M or more.

[0303] The term "antigen-binding module" refers to a polypeptide molecule that specifically binds to a target antigen. Specific antigen-binding modules include the antigen-binding domains of antibodies, for example, the heavy chain variable region and the light chain variable region. The term "antigen-binding module that specifically binds to CD3" refers to a module that can bind to CD3 or its epitope with sufficient affinity so that a molecule containing the module can be used as a diagnostic and / or therapeutic agent targeting CD3. For example, an antigen-binding module that specifically binds to CD3 has an equilibrium dissociation constant (KD) of < about 10 nM, which is measured by surface plasmon resonance assay. Antigen-binding modules include antibody fragments defined herein, for example, Fab, substituted Fab, or scFv.

[0304] The term "linker" refers to a linking unit that connects two polypeptide fragments. In this specification, linkers that appear in the same structural formula may be the same or different. The linker may be a peptide linker, containing one or more amino acids, typically containing about 1 to 30, 2 to 24, or 3 to 15 amino acids. Linkers used in this specification may be the same or different. When "-" appears in the structural formula, it indicates that the units on both sides are directly linked by a covalent bond.

[0305] "Tm" is the melting denaturation temperature (intrinsic fluorescence). When a protein is denatured (by heating or the action of a denaturing agent), its tertiary structure unfolds, and the microenvironment of aromatic amino acids changes, resulting in a change in the emission fluorescence spectrum. In this disclosure, Tm1 refers to the temperature at which the fluorescence changes to half of its maximum value.

[0306] "Tonset" is the onset temperature of denaturation. It means the temperature at which the protein begins to denature, that is, the temperature at which the fluorescence value begins to change.

[0307] "Tagg" is the aggregation onset temperature. Aggregates were detected at two wavelengths, 266 nm and 473 nm, by static light scattering, and the temperature at the onset of sample aggregation was monitored. Tagg 266 refers to monitoring the aggregation onset temperature at 266 nm.

[0308] The term "nucleic acid" may be used interchangeably herein with the term "polynucleotide" and refers to deoxyribonucleotides or ribonucleotides in single-stranded or double-stranded form and polymers thereof. The term covers nucleic acids containing known nucleoside analogs or modified backbone residues or linkers, which nucleic acids are synthetic, naturally occurring, and non-naturally occurring, having binding properties similar to a reference nucleic acid and being metabolized in the same manner as a reference nucleoside. Examples of such analogs include, but are not limited to, phosphorothioate, phosphoramidate, methylphosphonate, chiral-methylphosphonate, 2-O-methyl ribonucleotide, peptide-nucleic acid (PNA). An "isolated" nucleic acid refers to a nucleic acid molecule separated from the components of its natural environment. Isolated nucleic acids include nucleic acid molecules contained in the following cells, which cells generally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location different from its natural chromosomal location. The isolated nucleic acid encoding the antigen-binding molecule refers to one or more nucleic acid molecules encoding the heavy and light chains (or fragments thereof) of an antibody, such one or more nucleic acid molecules contained in a single vector or separate vectors, and such one or more nucleic acid molecules present at one or more locations in a host cell. Unless otherwise specified, a particular nucleic acid sequence also implicitly covers its conservatively modified variants (e.g., degenerate codon substitutions) and complementary sequences, as well as the explicitly recited sequence. Specifically, as detailed below, degenerate codon substitutions can be obtained by producing a sequence in which the third position of one or more selected (or all) codons is substituted with a degenerate base and / or deoxyinosine residue.

[0309] Although specific coding nucleotide sequences are not provided in the present disclosure, those skilled in the art should understand that the corresponding coding nucleotide sequences can be determined based on the amino acid sequences according to the codon rules and the host codon bias.

[0310] The terms "polypeptide" and "protein" may be used interchangeably herein and refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimics corresponding to naturally occurring amino acids, and apply to both naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. Unless otherwise specified, a particular polypeptide sequence implicitly further covers its conservatively modified variants.

[0311] The term "sequence identity" refers to the degree (percentage) to which the amino acids / nucleic acids of two sequences are identical at equivalent positions when the two sequences are optimally aligned. Gaps can be introduced as necessary during the alignment so as to obtain the maximum percentage of sequence identity, and any conservative substitutions are not considered part of the sequence identity. To measure the percentage of sequence identity, the alignment can be achieved by publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software, which are techniques known in the art. Those skilled in the art can determine the parameters applied to the measurement alignment, including any algorithms necessary to achieve a maximum alignment over the entire length of the sequences being compared.

[0312] The term "fusion" or "linkage" refers to the covalent attachment of elements (e.g., an antigen-binding module and an Fc domain) directly or via a linker.

[0313] The term "vector" refers to a polynucleotide molecule capable of transporting another polynucleotide linked thereto. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop that can be ligated to an added DNA segment. Another type of vector is a viral vector, such as an adeno-associated virus vector (AAV or AAV2), in which another DNA segment can be ligated to the viral genome. Some vectors can self-replicate in the host cells into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can replicate with the host genome by integrating into the host cell's genome after being introduced into the host cell. The term "expression vector" or "expression construct" refers to a vector that contains (along with the host cell) a nucleic acid sequence useful for transformation of a host cell and that directs and / or controls the expression of one or more heterologous coding regions operably linked thereto. An expression construct may include, but is not limited to, sequences that affect or control transcription, translation, and RNA splicing of a coding region operably linked thereto when an intron is present.

[0314] The terms "host cell", "host cell line", and "host cell culture" may be used interchangeably and refer to a cell into which an exogenous nucleic acid has been introduced, including the progeny of such a cell. Host cells include "transformants" and "transformed cells" and include the primary transformed cells and progeny derived therefrom without regard to the number of passages. The progeny may not be identical to the parental cell in nucleic acid content and may contain mutations. As used herein, the term includes mutant progeny having the same function or biological activity as the cells screened or selected from the primary transformed cells. Host cells include prokaryotic and eukaryotic host cells, among which eukaryotic host cells include, but are not limited to, mammalian cells, insect cell lines, plant cells, and fungal cells. Mammalian host cells include human, mouse, rat, dog, monkey, pig, goat, cow, horse, and hamster cells, including, but not limited to, Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, simian kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, and HEK-293 cells.Fungal cells include yeast and filamentous fungal cells, such as Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia spp., Saccharomyces cerevisiae, Saccharomyces spp., Hansenula polymorpha, Kluyveromyces spp., Kluyveromyces lactis, Candida albicans, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Trichoderma reesei, Chrysosporium lucknowense, Fusarium sp., Fusarium gramineum, Fusarium venenatum, Physcomitrella patens, Neurospora crassa, Aspergillus spp., Yarrowia lipolytica.It includes Pichia genus, any Saccharomyces genus, Hansenula polymorpha, any Kluyveromyces genus, Candida albicans, any Aspergillus genus, Trichoderma reesei, Chrysosporium lucknowense, any Fusarium genus, Yarrowia lipolytica and Neurospora crassa. The host cells of this patent do not include those not recognized by the patent law.

[0315] "Optional" or "optionally" means that the event or situation described thereafter may or may not occur, and this description includes both the case where the event or situation occurs and the case where it does not occur.

[0316] The term "pharmaceutical composition" refers to a mixture containing one or more antigen-binding molecules or antibodies described herein and other chemical components, and the above other components are, for example, physiologically / pharmaceutically acceptable carriers and excipients.

[0317] The term "pharmaceutically acceptable carrier, diluent, buffer or excipient" refers to a component that is non-toxic to the subject, different from the active ingredient in a drug formulation. Pharmaceutically acceptable carriers, diluents, buffers or excipients include, but are not limited to, buffers, excipients, stabilizers or preservatives.

[0318] The terms "subject" or "individual" include humans and non-human animals. Non-human animals include all vertebrates (e.g., mammals and non-mammals), such as non-human primates (e.g., cynomolgus monkeys), sheep, dogs, cows, chickens, amphibians, and reptiles. Unless otherwise specified, the above terms "patient" or "subject" may be used interchangeably herein. As used herein, the term "cyno" or "cynomolgus" refers to cynomolgus monkeys (Macaca fascicularis). In certain embodiments, the individual or subject is human.

[0319] "Administer" or "give", when applied to an animal, human, subject of an experiment, cell, tissue, organ, or biological fluid, means contact of an exogenous agent, therapeutic agent, diagnostic agent, or composition with the animal, human, subject, cell, tissue, organ, or biological fluid.

[0320] The term "sample" refers to an extract such as a fluid, cell, or tissue isolated from a subject, and a fluid, cell, or tissue present in the body of a subject. Exemplary samples are biological fluids, such as blood, serum and serous fluid, plasma, lymph, urine, saliva, cyst fluid, tears, excreta, sputum, mucosal secretions of secretory tissues and organs, vaginal secretions, ascites, pleural, pericardial, peritoneal, abdominal cavity, and other body cavity fluids, fluids collected from bronchoalveolar lavage fluid, synovial fluid, a liquid solution that has contacted a subject or biological source, such as cell and organ culture media (including cell or organ conditioned media), wash fluids, etc., tissue biopsy samples, fine needle aspiration tissues, surgically excised tissues, organ cultures, or cell cultures.

[0321] "Treatment" and "treating" (and their grammatical variations) refer to a clinical intervention to be administered to an individual to be treated and can be carried out for prophylaxis or in a clinical pathological process. Desired effects of treatment include, but are not limited to, prevention of the occurrence or recurrence of a disease, alleviation of symptoms, reduction / decrease of any direct or indirect pathological consequence of the disease, prevention of metastasis, reduction of the rate of disease progression, improvement or alleviation of the disease state, and regression or improvement of the prognosis. In some embodiments, use of the antigen-binding molecules of the present disclosure delays the formation or progression of a disease.

[0322] The terms "recurrence", "relapse", and "relapsed" mean that a cancer or disease recurs after it has been clinically determined that the disease has disappeared. A diagnosis of distant metastasis or local recurrence of cancer can be considered a recurrence.

[0323] "Effective amount" generally means an amount sufficient for reduction of the severity and / or frequency of symptoms, elimination of these symptoms and / or underlying causes, prevention of the appearance of symptoms and / or their underlying causes, and / or amelioration or improvement of damage caused by or associated with the disease state. In some examples, the effective amount is a therapeutically effective amount or a prophylactically effective amount.

[0324] "Therapeutically effective amount" means an amount sufficient for treatment of a disease state or symptoms, particularly a disease state or symptoms associated with the disease state, or for prevention, inhibition, delay or reversal of the progression of any other undesirable symptoms associated in any way with the disease state or the disease by any other means.

[0325] "Prophylactically effective amount" means an amount that, when administered to a subject, confers a predetermined prophylactic effect such as prevention (or recurrence) of onset of the disease state, or delay thereof, or reduction in the likelihood of onset (or recurrence) of the disease state or related symptoms. A complete therapeutic or prophylactic effect does not necessarily occur upon administration of a single dose, but may occur after a series of doses have been administered. Accordingly, a therapeutically or prophylactically effective amount can be administered in a single or multiple dose regimen. "Therapeutically effective amount" and "prophylactically effective amount" can vary depending on various factors such as, for example, the disease state of the individual, age, sex and weight, and the ability of the therapeutic agent or combination of therapeutic agents to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic agent or combination of therapeutic agents include, for example, improvement in the health state of the subject.

[0326] The antigen-binding molecules of the present disclosure The present disclosure provides antigen-binding molecules having many advantageous properties such as good in vitro killing activity, therapeutic activity, safety, pharmacokinetic properties, and drug discovery potential (e.g., yield, purity, and stability).

[0327] Exemplary antigen-binding molecules The antigen-binding molecules of the present disclosure include bispecific antigen-binding molecules (e.g., bispecific antibodies) and anti-DLL3 antibodies that specifically bind to DLL3 and CD3. In particular, the antigen-binding molecules of the present disclosure have any one of the following properties: a. High affinity for DLL3. In some embodiments, the anti-DLL3 antibody or antigen-binding molecule has a dissociation constant (Kd) of 4×10 -9 M, 3×10 -9 M, 2×10 -9 M, 1×10 -9 M, 9×10 -10 M, 8×10 -10 M, 7×10 -10 M, 6×10 -10 M, 5×10 -10 M, 4×10 -10 M, 3×10 -10 M, 2×10 -10 M, 1×10 -10 M, 9×10 -11Binds to human DLL3 with a KD less than M, where the KD is measured by surface plasmon resonance. In some embodiments, the antigen-binding molecule has a binding EC50 to the DLL3 protein of less than 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.09 nM, 0.08 nM, 0.07 nM, and the EC50 is detected by ELISA.

[0328] b. It has high affinity for DLL3 expressed on the cell surface. In some embodiments, the anti-DLL3 antibody has a binding EC50 to H1184 cells of less than 0.2 nM, 0.1 nM, 0.09 nM, 0.08 nM, 0.07 nM, 0.06 nM, 0.05 nM, 0.04 nM.

[0329] c. It has a specific killing effect on cells expressing DLL3. In some embodiments, the antigen-binding molecule can specifically kill SHP77 cells and H1184 cells expressing DLL3, and among them, the killing IC50 for H1184 cells is less than 30 pM, 25 pM, 20 pM, 15 pM, 14 pM, 13 pM, 12 pM, 11 pM, 10 pM, 9 pM, 8 pM, 7 pM.

[0330] d. It has in vitro activation activity on T cells. In some embodiments, the antigen-binding molecule activates Jurkat Lucia TM NFAT cells with an EC50 of less than 20 pM, 19 pM, 18 pM, 17 pM, 16 pM, 15 pM, 14 pM, 13 pM, 12 pM, 11 pM, 10 pM, 9 pM, 8 pM, 7 pM.

[0331] e. It induces the release of low levels of cytokines (IL6 and IFNγ).

[0332] e. It has more potent in vivo therapeutic activity. In some embodiments, the antigen-binding molecule can significantly inhibit the growth of subcutaneous transplanted tumors of mouse SHP77 and H1184 cells.

[0333] The present disclosure provides an antigen-binding molecule, which comprises at least one antigen-binding module that specifically binds to DLL3 and at least one antigen-binding module that specifically binds to CD3. The antigen-binding module that specifically binds to DLL3 as described above comprises DLL3-VH and DLL3-VL, and the antigen-binding module that specifically binds to CD3 as described above comprises CD3-VH and CD3-VL. The present disclosure further provides an anti-DLL3 antibody that can specifically bind to DLL3, and the antibody comprises DLL3-VH and DLL3-VL. Specifically, the examples in this specification disclose antibody series 6, 98, 110 and 30. Hereinafter, the antibodies or antigen-binding molecules in this specification will be described by taking antibodies 6 and 110 as examples.

[0334] An antigen-binding molecule that specifically binds to DLL3 and CD3, among which, the above-mentioned DLL3-VH has DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 22, and the above-mentioned DLL3-VL has DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 24, 71, 72 or 73, and DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 25 or 74.

[0335] An antigen-binding molecule or anti-DLL3 antibody that specifically binds to DLL3 and CD3, among which, the above-mentioned DLL3-VH has DLL3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 32, 96, 97, 98 or 99, and DLL3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 33, and the above-mentioned DLL3-VL has DLL3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 34, DLL3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 36.

[0336] An antigen-binding molecule that specifically binds to DLL3 and CD3, among which, The above DLL3-VH comprises DLL3-HCDR1 represented by SEQ ID NO: 20, DLL3-HCDR2 represented by SEQ ID NO: 21, 69 or 70, and DLL3-HCDR3 represented by SEQ ID NO: 22, and the above DLL3-VL comprises DLL3-LCDR1 represented by SEQ ID NO: 23, DLL3-LCDR2 represented by SEQ ID NO: 24, 71, 72 or 73, and DLL3-LCDR3 represented by SEQ ID NO: 25 or 74.

[0337] An antigen-binding molecule or an anti-DLL3 antibody that specifically binds to DLL3 and CD3, among which, The above DLL3-VH comprises DLL3-HCDR1 represented by SEQ ID NO: 20, DLL3-HCDR2 represented by SEQ ID NO: 32, 96, 97, 98 or 99, and DLL3-HCDR3 represented by SEQ ID NO: 33, and the above DLL3-VL comprises DLL3-LCDR1 represented by SEQ ID NO: 34, DLL3-LCDR2 represented by SEQ ID NO: 35, and DLL3-LCDR3 represented by SEQ ID NO: 36.

[0338] An antigen-binding molecule that specifically binds to DLL3 and CD3, among which, The above DLL3-VH comprises DLL3-HCDR1 represented by SEQ ID NO: 20, DLL3-HCDR2 represented by SEQ ID NO: 21, and DLL3-HCDR3 represented by SEQ ID NO: 22, and the above DLL3-VL comprises DLL3-LCDR1 represented by SEQ ID NO: 23, DLL3-LCDR2 represented by SEQ ID NO: 71, and DLL3-LCDR3 represented by SEQ ID NO: 25.

[0339] An antigen-binding molecule or an anti-DLL3 antibody that specifically binds to DLL3 and CD3, among which, The above DLL3-VH includes DLL3-HCDR1 represented by SEQ ID NO: 20, DLL3-HCDR2 represented by SEQ ID NO: 21, and DLL3-HCDR3 represented by SEQ ID NO: 22, and the above DLL3-VL includes DLL3-LCDR1 represented by SEQ ID NO: 23, DLL3-LCDR2 represented by SEQ ID NO: 24, and DLL3-LCDR3 represented by SEQ ID NO: 25, or The above DLL3-VH includes DLL3-HCDR1 represented by SEQ ID NO: 20, DLL3-HCDR2 represented by SEQ ID NO: 21, and DLL3-HCDR3 represented by SEQ ID NO: 22, and the above DLL3-VL includes DLL3-LCDR1 represented by SEQ ID NO: 23, DLL3-LCDR2 represented by SEQ ID NO: 72, and DLL3-LCDR3 represented by SEQ ID NO: 25, or The above DLL3-VH includes DLL3-HCDR1 represented by SEQ ID NO: 20, DLL3-HCDR2 represented by SEQ ID NO: 69, and DLL3-HCDR3 represented by SEQ ID NO: 22, and the above DLL3-VL includes DLL3-LCDR1 represented by SEQ ID NO: 23, DLL3-LCDR2 represented by SEQ ID NO: 71, and DLL3-LCDR3 represented by SEQ ID NO: 74, or The above DLL3-VH includes DLL3-HCDR1 represented by SEQ ID NO: 20, DLL3-HCDR2 represented by SEQ ID NO: 69, and DLL3-HCDR3 represented by SEQ ID NO: 22, and the above DLL3-VL includes DLL3-LCDR1 represented by SEQ ID NO: 23, DLL3-LCDR2 represented by SEQ ID NO: 24, and DLL3-LCDR3 represented by SEQ ID NO: 74, or The above DLL3-VH includes DLL3-HCDR1 represented by SEQ ID NO: 20, DLL3-HCDR2 represented by SEQ ID NO: 69, and DLL3-HCDR3 represented by SEQ ID NO: 22, and the above DLL3-VL includes DLL3-LCDR1 represented by SEQ ID NO: 23, DLL3-LCDR2 represented by SEQ ID NO: 71, and DLL3-LCDR3 represented by SEQ ID NO: 25, or The above DLL3-VH contains DLL3-HCDR1 shown in SEQ ID NO: 20, DLL3-HCDR2 shown in SEQ ID NO: 70, and DLL3-HCDR3 shown in SEQ ID NO: 22, and the above DLL3-VL contains DLL3-LCDR1 shown in SEQ ID NO: 23, DLL3-LCDR2 shown in SEQ ID NO: 71, and DLL3-LCDR3 shown in SEQ ID NO: 25, or The above DLL3-VH contains DLL3-HCDR1 shown in SEQ ID NO: 20, DLL3-HCDR2 shown in SEQ ID NO: 70, and DLL3-HCDR3 shown in SEQ ID NO: 22, and the above DLL3-VL contains DLL3-LCDR1 shown in SEQ ID NO: 23, DLL3-LCDR2 shown in SEQ ID NO: 24, and DLL3-LCDR3 shown in SEQ ID NO: 74.

[0340] An antigen-binding molecule or an anti-DLL3 antibody that specifically binds to DLL3 and CD3, among which, The above DLL3-VH contains DLL3-HCDR1 shown in SEQ ID NO: 20, DLL3-HCDR2 shown in SEQ ID NO: 96, and DLL3-HCDR3 shown in SEQ ID NO: 33, and the above DLL3-VL contains DLL3-LCDR1 shown in SEQ ID NO: 34, DLL3-LCDR2 shown in SEQ ID NO: 35, and DLL3-LCDR3 shown in SEQ ID NO: 36.

[0341] In some embodiments, the above antigen-binding molecule or anti-DLL3 antibody, the above DLL3-VH and / or the above DLL3-VL are of murine or humanized origin. In some embodiments, the above DLL3-VH and / or the above DLL3-VL are of humanized origin.

[0342] In some embodiments, the FR1, FR2, FR3, and FR4 of the humanized DLL3-VH have at least 60%, 70%, 80%, or 90% sequence identity with the FR1, FR2, FR3, and FR4 of SEQ ID NO: 50, 51, or 52, and the FR1, FR2, FR3, and FR4 of the humanized DLL3-VL have at least 60%, 70%, 80%, or 90% sequence identity with the FR1, FR2, FR3, and FR4 of SEQ ID NO: 62 or 68.

[0343] In some embodiments, the humanized DLL3-VH has FR1, FR2, FR3 derived from IGHV1-3*01, IGHV7-4-1*02, or IGHV3-73*01, and FR4 derived from IGHJ6*01, and it is either unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 27Y, 30T, 38K, 43K, 48I, 67A, 68A, 69L, 71V, 73K, 75S, 76N, and 93A, and / or the humanized DLL3-VL has FR1, FR2, FR3 derived from IGKV1-16*01 or IGKV3-20*02, and FR4 derived from IGKJ4*01, and it is either unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1N, 36L, 42K, 43S, 44F, 46G, 69A, 71Y, 79Q, and 85D. In some embodiments, the amino acid positions in the variable region are defined according to the Kabat numbering convention.

[0344] In some embodiments, the humanized DLL3-VH comprises the amino acid sequence of SEQ ID NO: 50 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 1E, 43K, 48I, 67A, 69L, 71V, 73K, and 76N in the FR region of SEQ ID NO: 50.

[0345] In some embodiments, the humanized DLL3-VH comprises the amino acid sequence of SEQ ID NO: 51 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 1E, 5Q, 38K, 68A, 69L, 71V, 73K, 75S, and 76N in the FR region of SEQ ID NO: 51.

[0346] In some embodiments, the humanized DLL3-VH comprises the amino acid sequence of SEQ ID NO: 52 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 27Y, 30T, 69L, 71V, 73K, and 93A in the FR region of SEQ ID NO: 52.

[0347] In some embodiments, the humanized DLL3-VL comprises the amino acid sequence of SEQ ID NO: 62 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 36L, 43S, 44F, 46G, 69A, 71Y, and 85D in the FR region of SEQ ID NO: 62.

[0348] In some embodiments, the humanized DLL3-VL comprises the amino acid sequence of SEQ ID NO: 68 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 36L, 42K, 46G, 69A, 71Y, 79Q, and 85D in the FR region of SEQ ID NO: 68.

[0349] In some embodiments, the FR1, FR2, FR3, and FR4 of the humanized DLL3-VH have at least 60%, 70%, 80%, or 90% sequence identity with the FR1, FR2, FR3, and FR4 of SEQ ID NO: 95, and the FR1, FR2, FR3, and FR4 of the humanized DLL3-VL have at least 60%, 70%, 80%, or 90% sequence identity with the FR1, FR2, FR3, and FR4 of SEQ ID NO: 88.

[0350] In some embodiments, the humanized DLL3-VH has FR1, FR2, and FR3 derived from IGHV1-3*01 and FR4 derived from IGHJ6*01, and it is either unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1E, 24T, 44S, 71V, and 73K, and / or the humanized DLL3-VL has FR1, FR2, and FR3 derived from IGKV4-1*01 and FR4 derived from IGKJ2*01, and it is either unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1N, 9K, 43S, 68A, and 85D. In some embodiments, the amino acid positions in the variable region are defined according to the Kabat numbering convention.

[0351] In some embodiments, the humanized DLL3-VH comprises the amino acid sequence of SEQ ID NO: 95 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 1E, 24T, 44S, 71V, and 73K in the FR region of SEQ ID NO: 95. In some embodiments, the humanized DLL3-VL comprises the amino acid sequence of SEQ ID NO: 88 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 1N, 9K, 43S, 68A, and 85D in the FR region of SEQ ID NO: 88.

[0352] In some embodiments, the humanized DLL3-VH comprises the amino acid sequence of SEQ ID NO: 51 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 1E, 38K, 68A, 69L, 71V, 73K, 75S, and 76N in the FR region of SEQ ID NO: 51, and the humanized DLL3-VL comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 63. In some embodiments, the amino acid substitutions are one or more amino acid substitutions selected from the group consisting of 43S and 44F.

[0353] In some embodiments, the humanized DLL3-VH comprises the amino acid sequence of SEQ ID NO: 91, or a variant of SEQ ID NO: 91. In some embodiments, the variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 91, and the humanized DLL3-VL comprises the amino acid sequence of SEQ ID NO: 88 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 1N, 9K, 43S, 68A, and 85D in the FR region of SEQ ID NO: 88.

[0354] In some embodiments, the variable region and CDR are defined according to the Kabat numbering rule.

[0355] In some embodiments, the antigen-binding molecule according to any one of the above, wherein the amino acid sequence of the DLL3-VH has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 12, 43, 44, 45, 46, 47, 48, 49, 5, 51, 52, 53, 54, 55, 56 or 57, and the amino acid sequence of the DLL3-VL has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 13, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67 or 68. In some embodiments, the amino acid sequence of the DLL3-VH is represented by SEQ ID NO: 12, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 or 57, and the amino acid sequence of the DLL3-VL is represented by SEQ ID NO: 13, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67 or 68.

[0356] In some embodiments, the anti-DLL3 antibody described in any one of the above, wherein the amino acid sequence of the DLL3-VH has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 or 57, and the amino acid sequence of the DLL3-VL has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 63, 64, 65, 66 or 67. In some embodiments, the amino acid sequence of the DLL3-VH is represented by SEQ ID NO: 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 or 57, and the amino acid sequence of the DLL3-VL is represented by SEQ ID NO: 63, 64, 65, 66 or 67.

[0357] In some embodiments, the anti-DLL3 antibody described in any one of the above, wherein the amino acid sequence of the DLL3-VH has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 56 or 57, and the amino acid sequence of the DLL3-VL has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 58, 59, 60, 61, 62, 63, 64, 65, 66, 67 or 68. In some embodiments, the amino acid sequence of the DLL3-VH is represented by SEQ ID NO: 56 or 57, and the amino acid sequence of the DLL3-VL is represented by SEQ ID NO: 58, 59, 60, 61, 62, 63, 64, 65, 66, 67 or 68.

[0358] In some embodiments, the antigen-binding molecule or anti-DLL3 antibody described in any one of the above, wherein the amino acid sequence of the DLL3-VH is represented by SEQ ID NO: 54, and the amino acid sequence of the DLL3-VL is represented by SEQ ID NO: 63, or the amino acid sequence of the DLL3-VH is represented by SEQ ID NO: 54, and the amino acid sequence of the DLL3-VL is represented by SEQ ID NO: 61, or The amino acid sequence of the above DLL3-VH is shown by SEQ ID NO: 54, and the amino acid sequence of the above DLL3-VL is shown by SEQ ID NO: 64, or The amino acid sequence of the above DLL3-VH is shown by SEQ ID NO: 56, and the amino acid sequence of the above DLL3-VL is shown by SEQ ID NO: 65, or The amino acid sequence of the above DLL3-VH is shown by SEQ ID NO: 56, and the amino acid sequence of the above DLL3-VL is shown by SEQ ID NO: 67, or The amino acid sequence of the above DLL3-VH is shown by SEQ ID NO: 56, and the amino acid sequence of the above DLL3-VL is shown by SEQ ID NO: 65, or The amino acid sequence of the above DLL3-VH is shown by SEQ ID NO: 57, and the amino acid sequence of the above DLL3-VL is shown by SEQ ID NO: 65, or The amino acid sequence of the above DLL3-VH is shown by SEQ ID NO: 57, and the amino acid sequence of the above DLL3-VL is shown by SEQ ID NO: 67, or The amino acid sequence of the above DLL3-VH is shown by SEQ ID NO: 57, and the amino acid sequence of the above DLL3-VL is shown by SEQ ID NO: 65.

[0359] In some embodiments, it is the antigen-binding molecule or anti-DLL3 antibody described in any one of the above, wherein the amino acid sequence of the above DLL3-VH has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 16, 89, 90, 91, 92, 93, 94 or 95, and the amino acid sequence of the above DLL3-VL has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID NO: 17, 86, 87 or 88. In some embodiments, the amino acid sequence of the above DLL3-VH is shown by SEQ ID NO: 16, 89, 90, 91, 92, 93, 94 or 95, and the amino acid sequence of the above DLL3-VL is shown by SEQ ID NO: 17, 86, 87 or 88.

[0360] In some embodiments, the antigen-binding molecule or anti-DLL3 antibody according to any one of the above, wherein the amino acid sequence of the DLL3-VH is represented by SEQ ID NO: 91, and the amino acid sequence of the DLL3-VL is represented by SEQ ID NO: 87.

[0361] In some embodiments, the anti-DLL3 antibody according to any one of the above, which comprises a heavy chain and a light chain, wherein, the amino acid sequence of the heavy chain is represented by SEQ ID NO: 121, and the amino acid sequence of the light chain is represented by SEQ ID NO: 122, or the amino acid sequence of the heavy chain is represented by SEQ ID NO: 125, and the amino acid sequence of the light chain is represented by SEQ ID NO: 126.

[0362] In some embodiments, the above antigen-binding molecule, wherein, i) the CD3-VH comprises CD3-HCDR1 represented by SEQ ID NO: 129, CD3-HCDR2 represented by SEQ ID NO: 130, and CD3-HCDR3 represented by SEQ ID NO: 131, and the CD3-VL comprises CD3-LCDR1 represented by SEQ ID NO: 132, CD3-LCDR2 represented by SEQ ID NO: 133, and CD3-LCDR3 represented by SEQ ID NO: 134, or ii) the CD3-VH comprises CD3-HCDR1 represented by SEQ ID NO: 129, CD3-HCDR2 represented by SEQ ID NO: 130, and CD3-HCDR3 represented by SEQ ID NO: 135, and the CD3-VL comprises CD3-LCDR1 represented by SEQ ID NO: 132, CD3-LCDR2 represented by SEQ ID NO: 133, and CD3-LCDR3 represented by SEQ ID NO: 134.

[0363] In some embodiments, the variable region and CDR are defined according to the Kabat numbering rule.

[0364] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the CD3-VH and / or the CD3-VL is murine or humanized. In some embodiments, the CD3-VH and / or the CD3-VL is humanized.

[0365] In some embodiments, the antigen-binding molecule described in any one of the above, wherein the amino acid sequence of the CD3-VH is represented by SEQ ID NO: 136 or 138, and the amino acid sequence of the CD3-VL is represented by SEQ ID NO: 137.

[0366] In some embodiments, the antigen-binding molecule described in any one of the above, which a first chain represented by SEQ ID NO: 152, a second chain represented by SEQ ID NO: 153, a third chain represented by SEQ ID NO: 154, and a fourth chain represented by SEQ ID NO: 155, or a first chain represented by SEQ ID NO: 152, a second chain represented by SEQ ID NO: 153, a third chain represented by SEQ ID NO: 156, and a fourth chain represented by SEQ ID NO: 155.

[0367] In some embodiments, the antigen-binding molecule described in any one of the above, which a first chain represented by SEQ ID NO: 157, a second chain represented by SEQ ID NO: 158, a third chain represented by SEQ ID NO: 159, or a first chain represented by SEQ ID NO: 157, a second chain represented by SEQ ID NO: 158, and a third chain represented by SEQ ID NO: 160.

[0368] In some embodiments, the antigen-binding molecule described in any one of the above, which a first chain represented by SEQ ID NO: 161, a second chain represented by SEQ ID NO: 162, or a first chain represented by SEQ ID NO: 163, a second chain represented by SEQ ID NO: 162, or a first chain represented by SEQ ID NO: 185, a second chain represented by SEQ ID NO: 162, or The first chain represented by SEQ ID NO: 186, the second chain represented by SEQ ID NO: 162, or The first chain represented by SEQ ID NO: 259, the second chain represented by SEQ ID NO: 162, or The first chain represented by SEQ ID NO: 260, the second chain represented by SEQ ID NO: 162, or The first chain represented by SEQ ID NO: 187, the second chain represented by SEQ ID NO: 188, or The first chain represented by SEQ ID NO: 187, the second chain represented by SEQ ID NO: 189, or The first chain represented by SEQ ID NO: 190, the second chain represented by SEQ ID NO: 188, or The first chain represented by SEQ ID NO: 190, the second chain represented by SEQ ID NO: 189, or The first chain represented by SEQ ID NO: 191, the second chain represented by SEQ ID NO: 188, or The first chain represented by SEQ ID NO: 191, the second chain represented by SEQ ID NO: 189, and includes

[0369] In some embodiments, it is an antigen-binding molecule according to any one of the above, and it The first chain represented by SEQ ID NO: 171, the second chain represented by SEQ ID NO: 172, the third chain represented by SEQ ID NO: 154, the fourth chain represented by SEQ ID NO: 155, or The first chain represented by SEQ ID NO: 171, the second chain represented by SEQ ID NO: 172, the third chain represented by SEQ ID NO: 156, the fourth chain represented by SEQ ID NO: 155, and includes

[0370] In some embodiments, it is an antigen-binding molecule according to any one of the above, and it The first chain represented by SEQ ID NO: 173, the second chain represented by SEQ ID NO: 174, the third chain represented by SEQ ID NO: 159, or The first chain represented by SEQ ID NO: 173, the second chain represented by SEQ ID NO: 174, the third chain represented by SEQ ID NO: 160, and includes

[0371] In some embodiments, it is an antigen-binding molecule according to any one of the above, and it The first chain represented by SEQ ID NO: 175, the second chain represented by SEQ ID NO: 176, or the first chain represented by SEQ ID NO: 177 and the second chain represented by SEQ ID NO: 176.

[0372] The antigen-binding molecules comprising antibody series 98 and 30 disclosed by the examples herein have a technical scope equivalent to that of the above-described antibody series 6 and 110.

[0373] Structure of the antigen-binding molecule The bispecific antigen-binding molecules of the present disclosure are not limited to a specific molecular structure as long as they have the desired antigen-binding function. For example, the bispecific antigen-binding molecules herein may be bivalent (1 + 1), trivalent (2 + 1), or tetravalent (2 + 2). The antigen-binding modules in the antigen-binding molecule may be any antibody fragment having antigen-binding activity that is fused via a peptide linker. The peptide linkers of the present disclosure (e.g., linker 1 to 8) may be any suitable peptide chain as long as the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker may be a flexible peptide containing 1 to 50 or 3 to 20 amino acid residues. In some embodiments, the above peptide linkers each independently have a structure of (GGGGS)n, where n is 1, 2, or 3. In some embodiments, the sequences of linker 1 and linker 2 are both GGGGS (SEQ ID NO: 147). In some embodiments, the sequence of linker 3 is GGGGSGGGGSGGGGS (SEQ ID NO: 148). In some embodiments, the sequence of linker 4 is GGGGS (SEQ ID NO: 147). In some embodiments, the sequence of linker 5 is GGGSGGGG (SEQ ID NO: 149). In some embodiments, the sequences of linker 6 and linker 8 are G (SEQ ID NO: 150). In some embodiments, the sequence of linker 7 is GGGGSGGGG (SEQ ID NO: 151).

[0374] Exemplarily, the antigen-binding molecule of the present disclosure has one first chain having a structure represented by formula (a-1), one second chain having a structure represented by formula (b-1), one third chain having a structure represented by formula (c), and one fourth chain having a structure represented by formula (d), (a-1) [DLL3-VH]-[GGGGS]-[Titin chain]-[Fc2], (b-1) [DLL3-VL]-[GGGGS]-[Obscurin chain], (c) [CD3-VH]-[CH1]-[Fc1], (d) [CD3-VL]-[CL], The structures represented by formulas (a-1), (b-1), (c), and (d) are arranged in sequence from the N-terminus to the C-terminus.

[0375] Exemplary antigen-binding molecules are one first chain represented by SEQ ID NO: 171, one second chain represented by SEQ ID NO: 172, one third chain represented by SEQ ID NO: 154, and one fourth chain represented by SEQ ID NO: 155, or one first chain represented by SEQ ID NO: 171, one second chain represented by SEQ ID NO: 172, one third chain represented by SEQ ID NO: 156, and one fourth chain represented by SEQ ID NO: 155, or one first chain represented by SEQ ID NO: 152, one second chain represented by SEQ ID NO: 153, one third chain represented by SEQ ID NO: 154, and one fourth chain represented by SEQ ID NO: 155, or one first chain represented by SEQ ID NO: 152, one second chain represented by SEQ ID NO: 153, one third chain represented by SEQ ID NO: 156, and one fourth chain represented by SEQ ID NO: 155, or one first chain represented by SEQ ID NO: 164, one second chain represented by SEQ ID NO: 165, one third chain represented by SEQ ID NO: 154, and one fourth chain represented by SEQ ID NO: 155, or one first chain represented by SEQ ID NO: 164, one second chain represented by SEQ ID NO: 165, one third chain represented by SEQ ID NO: 156, and one fourth chain represented by SEQ ID NO: 155, or One first chain represented by SEQ ID NO: 178, one second chain represented by SEQ ID NO: 179, one third chain represented by SEQ ID NO: 154, one fourth chain represented by SEQ ID NO: 155, or comprises one first chain represented by SEQ ID NO: 178, one second chain represented by SEQ ID NO: 179, one third chain represented by SEQ ID NO: 156, and one fourth chain represented by SEQ ID NO: 155.

[0376] Exemplarily, the antigen-binding molecule comprises one first chain having a structure represented by formula (e), one second chain having a structure represented by formula (f), and one third chain having a structure represented by formula (g-1), (e) [DLL3-VL]-[CL], (f) [DLL3-VL]-[CH1]-[Fc2], (g-1) [CD3-VH]-[GGGGSGGGGSGGGGS]-[CD3-VL]-[GGGGS]-[Fc1], and the structures represented by formulas (e), (f), and (g-1) are arranged in sequence from the N-terminus to the C-terminus.

[0377] Exemplary antigen-binding molecules are one first chain represented by SEQ ID NO: 173, one second chain represented by SEQ ID NO: 174, one third chain represented by SEQ ID NO: 160, or one first chain represented by SEQ ID NO: 173, one second chain represented by SEQ ID NO: 174, one third chain represented by SEQ ID NO: 159, or one first chain represented by SEQ ID NO: 157, one second chain represented by SEQ ID NO: 158, one third chain represented by SEQ ID NO: 159, or one first chain represented by SEQ ID NO: 157, one second chain represented by SEQ ID NO: 158, one third chain represented by SEQ ID NO: 160, or one first chain represented by SEQ ID NO: 166, one second chain represented by SEQ ID NO: 167, one third chain represented by SEQ ID NO: 159, or One first chain represented by SEQ ID NO: 166, one second chain represented by SEQ ID NO: 167, one third chain represented by SEQ ID NO: 160, or One first chain represented by SEQ ID NO: 180, one second chain represented by SEQ ID NO: 181, one third chain represented by SEQ ID NO: 159, or One first chain represented by SEQ ID NO: 180, one second chain represented by SEQ ID NO: 181, and one third chain represented by SEQ ID NO: 160.

[0378] Exemplarily, the antigen-binding molecule includes one first chain having a structure represented by formula (i-1) and one second chain having a structure represented by formula (h-1), (h-1)[DLL3-VL]-[GGGSGGGG]-[CD3-VH]-[G]-[Fc1], (i-1)[CD3-VL]-[GGGGSGGGG]-[DLL3-VH]-[G]-[Fc2], and The structures represented by formula (h-1) and (i-1) are arranged from the N-terminus to the C-terminus.

[0379] Exemplary antigen-binding molecules are One first chain represented by SEQ ID NO: 185 and one second chain represented by SEQ ID NO: 162, or One first chain represented by SEQ ID NO: 161 and one second chain represented by SEQ ID NO: 162, or One first chain represented by SEQ ID NO: 163 and one second chain represented by SEQ ID NO: 162, or One first chain represented by SEQ ID NO: 259 and one second chain represented by SEQ ID NO: 162, or One first chain represented by SEQ ID NO: 260 and one second chain represented by SEQ ID NO: 162, or One first chain represented by SEQ ID NO: 168 and one second chain represented by SEQ ID NO: 169, or One first chain represented by SEQ ID NO: 170 and one second chain represented by SEQ ID NO: 169, or One first chain represented by SEQ ID NO: 175, one second chain represented by SEQ ID NO: 176, or One first chain represented by SEQ ID NO: 177, one second chain represented by SEQ ID NO: 176, or One first chain represented by SEQ ID NO: 182, one second chain represented by SEQ ID NO: 183, or One first chain represented by SEQ ID NO: 184, one second chain represented by SEQ ID NO: 183, or One first chain represented by SEQ ID NO: 186, one second chain represented by SEQ ID NO: 162, or One first chain represented by SEQ ID NO: 187, one second chain represented by SEQ ID NO: 188, or One first chain represented by SEQ ID NO: 187, one second chain represented by SEQ ID NO: 189, or One first chain represented by SEQ ID NO: 190, one second chain represented by SEQ ID NO: 188, or One first chain represented by SEQ ID NO: 190, one second chain represented by SEQ ID NO: 189, or One first chain represented by SEQ ID NO: 191, one second chain represented by SEQ ID NO: 188, or One first chain represented by SEQ ID NO: 191 and one second chain represented by SEQ ID NO: 189.

[0380] Variant of the antigen-binding molecule In certain embodiments, amino acid sequence variants of the antigen-binding molecules provided herein are covered. For example, it is expected to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibody can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletion and / or insertion and / or substitution of residues in the amino acid sequence of the antigen-binding molecule. If the final construct has the desired properties such as antigen-binding properties, the final construct can be obtained by performing any combination of deletions, insertions and substitutions.

[0381] Substitutions, insertions, and deletions of variants In certain embodiments, variants of antigen-binding molecules having one or more amino acid substitutions are provided. Substitutions can be made in the CDRs and FRs. Conservative substitutions are shown in Table 2...

Claims

1. An antigen-binding molecule that specifically binds to DLL3 and CD3, comprising at least one antigen-binding module that specifically binds to DLL3 and at least one antigen-binding module that specifically binds to CD3, The antigen-binding module that specifically binds to the aforementioned DLL3 includes a heavy chain variable region DLL3-VH and a light chain variable region DLL3-VL. The antigen-binding module that specifically binds to CD3 includes a heavy chain variable region CD3-VH and a light chain variable region CD3-VL, of which, i) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69, or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, 24, 72, or 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25 or 74, or ii) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26 or 84, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85 or 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83 or 28, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or iii) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, 32, 97, 98, or 99, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, or iv) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, 37, 117, 118, or 120, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO:

40. Preferably, i) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or ii) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 28, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or iii) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, or iv) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40, more, The aforementioned antigen-binding molecule is 4 × 10⁶ under conditions of 25°C. －９ It binds to human DLL3 with a KD of less than M, and the KD is measured by surface plasmon resonance. An antigen-binding molecule that specifically binds to DLL3 and CD3.

2. i) The CD3-VH comprises CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 131, and the CD3-VL comprises CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 134, or ii) The CD3-VH comprises CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 129, CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 130, and CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 135, and the CD3-VL comprises CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 132, CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 133, and CD3-LCDR3 containing the amino acid sequence of SEQ ID NO:

134. An antigen-binding molecule that specifically binds to DLL3 and CD3 as described in claim 1.

3. i) The DLL3-VH contains the amino acid sequence of SEQ ID NOs. 54, 12, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, or 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NOs. 63, 13, 58, 59, 60, 61, 62, 64, 65, 66, 67, or 68, or ii) The DLL3-VH contains the amino acid sequence of SEQ ID NOs. 81, 14, 78, 79, 80, or 82, and the DLL3-VL contains the amino acid sequence of SEQ ID NOs. 77, 15, 75, or 76, or iii) The DLL3-VH contains the amino acid sequence of SEQ ID NOs. 91, 16, 89, 90, 92, 93, 94, or 95, and the DLL3-VL contains the amino acid sequence of SEQ ID NOs. 87, 17, 86, or 88, or iv) The DLL3-VH contains the amino acid sequence of SEQ ID NOs: 109, 18, 105, 106, 107, 108, 110, 111, 112, 113, 114, 115 or 116, and the DLL3-VL contains the amino acid sequence of SEQ ID NOs: 100, 19, 101, 102, 103 or 104, Preferably, i) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 63, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 61, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 64, or The DLL3-VH comprises the amino acid sequence of SEQ ID NO: 56, and the DLL3-VL comprises the amino acid sequence of SEQ ID NO: 65, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, or ii) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 77, or iii) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 87, or iv) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the DLL3-VL contains the amino acid sequence of SEQ ID NO:

100. An antigen-binding molecule that specifically binds to DLL3 and CD3 as described in claim 1.

4. i) CD3-VH contains the amino acid sequence of SEQ ID NO: 136, and CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or ii) CD3-VH contains the amino acid sequence of SEQ ID NO: 138, and CD3-VL contains the amino acid sequence of SEQ ID NO:

137. An antigen-binding molecule that specifically binds to DLL3 and CD3 as described in claim 1.

5. The antigen-binding module that specifically binds to the aforementioned DLL3 comprises a Titin chain and an Obscurin chain capable of forming a dimer, or The antigen-binding module that specifically binds to the aforementioned CD3 includes a Titin chain and an Obscurin chain capable of forming a dimer. Preferably, The titin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 192 to 210. The Obscurin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 211 to 251. more, The titin chain contains the amino acid sequence of SEQ ID NO: 208, and the obscurin chain contains the amino acid sequence of SEQ ID NO:

246. An antigen-binding molecule that specifically binds to DLL3 and CD3 as described in claim 1.

6. It includes an Fc region, the Fc region is preferably a human IgG Fc region, and more preferably a human IgG1 Fc region. More preferably, the Fc region includes one or more amino acid substitutions that can reduce the binding between the Fc region and the Fcγ receptor. Most preferably, the Fc region is human IgG1 It is an Fc region, and the amino acids at positions 234 and 235 are A, and are numbered according to the EU index. An antigen-binding molecule that specifically binds to DLL3 and CD3 as described in claim 1.

7. The molecule includes an Fc region, the Fc region comprising a first subunit Fc1 and a second subunit Fc2 that can associate with each other, and each of Fc1 and Fc2 independently has one or more amino acid substitutions that reduce homodimerization of the Fc region. Preferably, Fc1 has a knob structure using knob-in-hole technology, and Fc2 has a hole structure using knob-in-hole technology. More preferably, Fc1 has an amino acid W at position 366, and Fc2 has an amino acid S at position 366, an amino acid A at position 368, and an amino acid V at position 407, and is numbered according to the EU index. Most preferably, Fc1 comprises the amino acid sequence of SEQ ID NO: 143 and Fc2 comprises the amino acid sequence of SEQ ID NO: 144, or Fc1 comprises the amino acid sequence of SEQ ID NO: 145 and Fc2 comprises the amino acid sequence of SEQ ID NO:

146. An antigen-binding molecule that specifically binds to DLL3 and CD3 as described in claim 1.

8. The antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3, wherein the antigen-binding module that specifically binds to DLL3 is a substituted Fab containing a Titin chain and an Obscurin chain capable of forming a dimer, and the antigen-binding module that specifically binds to CD3 is a Fab, or The antigen-binding module that specifically binds to the aforementioned DLL3 is a Fab, and the antigen-binding module that specifically binds to the aforementioned CD3 is a substituted Fab containing a Titin chain and an Obscurin chain capable of forming a dimer. Preferably, The antigen-binding molecule that specifically binds to DLL3 and CD3 comprises a first chain having the structure shown in formula (a), a second chain having the structure shown in formula (b), a third chain having the structure shown in formula (c), and a fourth chain having the structure shown in formula (d). Formula (a) [DLL3-VH]-[Linker 1]-[Titin chain]-[Fc2], Formula (b) [DLL3-VL]-[Linker2]-[Obscurin chain], Formula (c) [CD3-VH]-[CH1]-[Fc1], and Equation (d) is [CD3 - VL] - [CL], In which case, linker 1 and linker 2 are the same or different peptide linkers, or linker 1 and / or linker 2 do not exist. The structures shown in formulas (a), (b), (c), and (d) are arranged from the N-terminus to the C-terminus. The titin chain and the obscurin chain can be interchanged. The Fc1 and Fc2 can be interchanged. More preferably, the antigen-binding molecule that specifically binds to DLL3 and CD3 is: A first chain containing the amino acid sequence of SEQ ID NO: 171, a second chain containing the amino acid sequence of SEQ ID NO: 172, a third chain containing the amino acid sequence of SEQ ID NO: 154, a fourth chain containing the amino acid sequence of SEQ ID NO: 155, or A first chain containing the amino acid sequence of SEQ ID NO: 171, a second chain containing the amino acid sequence of SEQ ID NO: 172, a third chain containing the amino acid sequence of SEQ ID NO: 156, a fourth chain containing the amino acid sequence of SEQ ID NO: 155, or A first chain containing the amino acid sequence of SEQ ID NO: 152, a second chain containing the amino acid sequence of SEQ ID NO: 153, a third chain containing the amino acid sequence of SEQ ID NO: 154, a fourth chain containing the amino acid sequence of SEQ ID NO: 155, or A first chain containing the amino acid sequence of SEQ ID NO: 152, a second chain containing the amino acid sequence of SEQ ID NO: 153, a third chain containing the amino acid sequence of SEQ ID NO: 156, a fourth chain containing the amino acid sequence of SEQ ID NO: 155, or A first chain containing the amino acid sequence of SEQ ID NO: 164, a second chain containing the amino acid sequence of SEQ ID NO: 165, a third chain containing the amino acid sequence of SEQ ID NO: 154, a fourth chain containing the amino acid sequence of SEQ ID NO: 155, or A first chain containing the amino acid sequence of SEQ ID NO: 164, a second chain containing the amino acid sequence of SEQ ID NO: 165, a third chain containing the amino acid sequence of SEQ ID NO: 156, a fourth chain containing the amino acid sequence of SEQ ID NO: 155, or A first chain containing the amino acid sequence of SEQ ID NO: 178, a second chain containing the amino acid sequence of SEQ ID NO: 179, a third chain containing the amino acid sequence of SEQ ID NO: 154, a fourth chain containing the amino acid sequence of SEQ ID NO: 155, or It has a first chain containing the amino acid sequence of SEQ ID NO: 178, a second chain containing the amino acid sequence of SEQ ID NO: 179, a third chain containing the amino acid sequence of SEQ ID NO: 156, and a fourth chain containing the amino acid sequence of SEQ ID NO:

155. The antigen-binding molecule described in claim 7, which specifically binds to DLL3 and CD3.

9. The antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3, wherein the antigen-binding module that specifically binds to DLL3 is Fab, and the antigen-binding module that specifically binds to CD3 is scFv. Preferably, The antigen-binding molecule that specifically binds to DLL3 and CD3 comprises a first chain having the structure shown in formula (e), a second chain having the structure shown in formula (f), and a third chain having the structure shown in formula (g). Formula (e) [DLL3-VL]-[CL], Formula (f) [DLL3-VH]-[CH1]-[Fc2], and Equation (g) is [CD3-VH]-[linker 3]-[CD3-VL]-[linker 4]-[Fc1], Of these, linker 3 and linker 4 are the same or different peptide linkers. The structures shown by equations (e), (f), and (g) are arranged from the N-terminus to the C-terminus. The Fc1 and Fc2 can be interchanged. More preferably, the antigen-binding molecule that specifically binds to DLL3 and CD3 is: A first chain containing the amino acid sequence of SEQ ID NO: 173, a second chain containing the amino acid sequence of SEQ ID NO: 174, and a third chain containing the amino acid sequence of SEQ ID NO: 160, or A first chain containing the amino acid sequence of SEQ ID NO: 173, a second chain containing the amino acid sequence of SEQ ID NO: 174, and a third chain containing the amino acid sequence of SEQ ID NO: 159, or A first chain containing the amino acid sequence of SEQ ID NO: 157, a second chain containing the amino acid sequence of SEQ ID NO: 158, and a third chain containing the amino acid sequence of SEQ ID NO: 159, or A first chain containing the amino acid sequence of SEQ ID NO: 157, a second chain containing the amino acid sequence of SEQ ID NO: 158, and a third chain containing the amino acid sequence of SEQ ID NO: 160, or A first chain containing the amino acid sequence of SEQ ID NO: 166, a second chain containing the amino acid sequence of SEQ ID NO: 167, and a third chain containing the amino acid sequence of SEQ ID NO: 159, or A first chain containing the amino acid sequence of SEQ ID NO: 166, a second chain containing the amino acid sequence of SEQ ID NO: 167, and a third chain containing the amino acid sequence of SEQ ID NO: 160, or A first chain containing the amino acid sequence of SEQ ID NO: 180, a second chain containing the amino acid sequence of SEQ ID NO: 181, and a third chain containing the amino acid sequence of SEQ ID NO: 159, or It has a first chain containing the amino acid sequence of SEQ ID NO: 180, a second chain containing the amino acid sequence of SEQ ID NO: 181, and a third chain containing the amino acid sequence of SEQ ID NO:

160. The antigen-binding molecule described in claim 7, which specifically binds to DLL3 and CD3.

10. The antigen-binding molecule comprises one antigen-binding module that specifically binds to DLL3 and one antigen-binding module that specifically binds to CD3. The antigen-binding molecule that specifically binds to DLL3 and CD3 comprises a first chain having the structure shown in formula (h) and a second chain having the structure shown in formula (i). Formula (h) [DLL3-VL]-[Linker 5]-[CD3-VH]-[Linker 6]-[Fc1], and Equation (i) is [CD3-VL]-[linker 7]-[DLL3-VH]-[linker 8]-[Fc2], Of these, linker 5, linker 6, linker 7 and linker 8 are the same or different peptide linkers. The structures shown by equations (h) and (i) are arranged from the N-terminus to the C-terminus, The Fc1 and Fc2 can be interchanged. Preferably, among them, i) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 63, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 61, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 64, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or ii) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 87, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or iii) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 77, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, or iv) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 100, and the CD3-VH contains the amino acid sequence of SEQ ID NO: 136 or 138, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 137, More preferably, the antigen-binding molecule that specifically binds to DLL3 and CD3 is: A first chain containing the amino acid sequence of SEQ ID NO: 185, and a second chain containing the amino acid sequence of SEQ ID NO: 162, or A first chain containing the amino acid sequence of SEQ ID NO: 161, and a second chain containing the amino acid sequence of SEQ ID NO: 162, or A first chain containing the amino acid sequence of SEQ ID NO: 163, and a second chain containing the amino acid sequence of SEQ ID NO: 162, or A first chain containing the amino acid sequence of SEQ ID NO: 259, and a second chain containing the amino acid sequence of SEQ ID NO: 162, or A first chain containing the amino acid sequence of SEQ ID NO: 260, and a second chain containing the amino acid sequence of SEQ ID NO: 162, or A first chain containing the amino acid sequence of SEQ ID NO: 168, and a second chain containing the amino acid sequence of SEQ ID NO: 169, or A first chain containing the amino acid sequence of SEQ ID NO: 170, and a second chain containing the amino acid sequence of SEQ ID NO: 169, or A first chain containing the amino acid sequence of SEQ ID NO: 175, and a second chain containing the amino acid sequence of SEQ ID NO: 176, or A first chain containing the amino acid sequence of SEQ ID NO: 177, and a second chain containing the amino acid sequence of SEQ ID NO: 176, or A first chain containing the amino acid sequence of SEQ ID NO: 182, and a second chain containing the amino acid sequence of SEQ ID NO: 183, or A first chain containing the amino acid sequence of SEQ ID NO: 184, and a second chain containing the amino acid sequence of SEQ ID NO: 183, or A first chain containing the amino acid sequence of SEQ ID NO: 186, and a second chain containing the amino acid sequence of SEQ ID NO: 162, or A first chain containing the amino acid sequence of SEQ ID NO: 187, and a second chain containing the amino acid sequence of SEQ ID NO: 188, or A first chain containing the amino acid sequence of SEQ ID NO: 187, and a second chain containing the amino acid sequence of SEQ ID NO: 189, or A first chain containing the amino acid sequence of SEQ ID NO: 190, and a second chain containing the amino acid sequence of SEQ ID NO: 188, or A first chain containing the amino acid sequence of SEQ ID NO: 190, and a second chain containing the amino acid sequence of SEQ ID NO: 189, or A first chain containing the amino acid sequence of SEQ ID NO: 191, and a second chain containing the amino acid sequence of SEQ ID NO: 188, or It has a first chain containing the amino acid sequence of SEQ ID NO: 191 and a second chain containing the amino acid sequence of SEQ ID NO:

189. The antigen-binding molecule described in claim 7, which specifically binds to DLL3 and CD3.

11. An anti-DLL3 antibody capable of specifically binding to DLL3, comprising a heavy chain variable region DLL3-VH and a light chain variable region DLL3-VL, of which, i) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69, or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69 or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 24, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69, or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69, or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69, or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69, or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, 69, or 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or ii) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26 or 84, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85 or 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83 or 28, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or iii) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, 32, 97, 98, or 99, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, or iv) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, 37, 117, 118, or 120, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO:

40. Preferably, i) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 21, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 72, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 73, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 74, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 69, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 70, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 22, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 23, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 71, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 25, or ii) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 84, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 85, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 83, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 26, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 27, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 28, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 29, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 30, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 31, or iii) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 96, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 33, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 34, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 36, or iv) The DLL3-VH comprises DLL3-HCDR1 containing the amino acid sequence of SEQ ID NO: 20, DLL3-HCDR2 containing the amino acid sequence of SEQ ID NO: 119, and DLL3-HCDR3 containing the amino acid sequence of SEQ ID NO: 38, and the DLL3-VL comprises DLL3-LCDR1 containing the amino acid sequence of SEQ ID NO: 39, DLL3-LCDR2 containing the amino acid sequence of SEQ ID NO: 35, and DLL3-LCDR3 containing the amino acid sequence of SEQ ID NO: 40, more, The aforementioned anti-DLL3 antibody was prepared at 25°C in 4 × 10⁶ conditions. －９ It binds to human DLL3 with a KD of less than M, and the KD is measured by surface plasmon resonance. Anti-DLL3 antibody.

12. It includes heavy chain variable region DLL3-VH and light chain variable region DLL3-VL, of which, i) The DLL3-VH contains the amino acid sequence of SEQ ID NOs. 54, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, or 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NOs. 63, 64, 65, 66, or 67, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 56 or 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 58, 59, 60, 61, 62, 63, 64, 65, 66, 67 or 68, or ii) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, 78, 79, 80, or 82, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 77, 75, or 76, or iii) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, 89, 90, 92, 93, 94, or 95, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 87, 86, or 88, or iv) The DLL3-VH contains the amino acid sequence of SEQ ID NOs: 109, 105, 106, 107, 108, 110, 111, 112, 113, 114, 115 or 116, and the DLL3-VL contains the amino acid sequence of SEQ ID NOs: 100, 101, 102, 103 or 104, Preferably, i) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 63, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 61, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 54, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 64, or The DLL3-VH comprises the amino acid sequence of SEQ ID NO: 56, and the DLL3-VL comprises the amino acid sequence of SEQ ID NO: 65, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 56, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 65, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 66, or The DLL3-VH contains the amino acid sequence of SEQ ID NO: 57, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 67, or ii) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 81, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 77, or iii) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 91, and the DLL3-VL contains the amino acid sequence of SEQ ID NO: 87, or iv) The DLL3-VH contains the amino acid sequence of SEQ ID NO: 109, and the DLL3-VL contains the amino acid sequence of SEQ ID NO:

100. The anti-DLL3 antibody according to claim 11.

13. The anti-DLL3 antibody is an antibody fragment, preferably Fab, Fab', F(ab')2, Fd, Fv, scFv, dsFv, or dAb. The anti-DLL3 antibody according to claim 11.

14. It comprises a heavy chain constant region and a light chain constant region, preferably the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 41 and / or the light chain constant region comprises the amino acid sequence of SEQ ID NO:

42. The anti-DLL3 antibody according to claim 11.

15. It includes heavy chains and light chains, of which, The heavy chain contains an amino acid sequence having at least 85% sequence identity with SEQ ID NO: 121, and the light chain contains an amino acid sequence having at least 85% sequence identity with SEQ ID NO: 122, or The heavy chain contains an amino acid sequence having at least 85% sequence identity with SEQ ID NO: 123, and the light chain contains an amino acid sequence having at least 85% sequence identity with SEQ ID NO: 124, or The heavy chain contains an amino acid sequence having at least 85% sequence identity with SEQ ID NO: 125, and the light chain contains an amino acid sequence having at least 85% sequence identity with SEQ ID NO: 126, or The heavy chain comprises an amino acid sequence having at least 85% sequence identity with SEQ ID NO: 127, and the light chain comprises an amino acid sequence having at least 85% sequence identity with SEQ ID NO:

128. Preferably, The heavy chain contains the amino acid sequence of SEQ ID NO: 121, and the light chain contains the amino acid sequence of SEQ ID NO: 122, or The heavy chain contains the amino acid sequence of SEQ ID NO: 123, and the light chain contains the amino acid sequence of SEQ ID NO: 124, or The heavy chain contains the amino acid sequence of SEQ ID NO: 125, and the light chain contains the amino acid sequence of SEQ ID NO: 126, or The heavy chain contains the amino acid sequence of SEQ ID NO: 127, and the light chain contains the amino acid sequence of SEQ ID NO:

128. The anti-DLL3 antibody according to claim 14.

16. A therapeutically effective amount comprising an antigen-binding molecule that specifically binds to DLL3 and CD3 according to any one of claims 1 to 10, or an anti-DLL3 antibody according to any one of claims 11 to 15, and one or more pharmaceutically acceptable carriers, diluents, buffers, or excipients. Pharmaceutical composition.

17. An antigen-binding molecule that specifically binds to DLL3 and CD3 according to any one of claims 1 to 10, or an anti-DLL3 antibody according to any one of claims 11 to 15, Isolated nucleic acid.

18. A nucleic acid comprising the isolated nucleic acid described in claim 17, host cell.

19. The use of an antigen-binding molecule that specifically binds to DLL3 and CD3 according to any one of claims 1 to 10, or an anti-DLL3 antibody according to any one of claims 11 to 15, in the preparation of a drug for treating a tumor or cancer, wherein the tumor or cancer is Selected from head and neck squamous cell carcinoma, head and neck cancer, brain cancer, glioma, glioblastoma multiforme, neuroblastoma, central nervous system cancer, neuroendocrine tumor, pharyngeal cancer, pharyngeal squamous cell carcinoma, oral squamous cell carcinoma, nasopharyngeal cancer, esophageal cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer, liver cancer, hepatobiliary cancer, pancreatic cancer, stomach cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, kidney cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, large cell lung cancer, triple-negative breast cancer, lymphoma, and small cell lung cancer. More preferably, the tumor or cancer is a tumor or cancer that expresses DLL3. use.

20. Use of the pharmaceutical composition according to claim 16, preferably, the tumor or cancer is Selected from head and neck squamous cell carcinoma, head and neck cancer, brain cancer, glioma, glioblastoma multiforme, neuroblastoma, central nervous system cancer, neuroendocrine tumor, pharyngeal cancer, pharyngeal squamous cell carcinoma, oral squamous cell carcinoma, nasopharyngeal cancer, esophageal cancer, thyroid cancer, malignant pleural mesothelioma, lung cancer, breast cancer, liver cancer, hepatobiliary cancer, pancreatic cancer, stomach cancer, gastrointestinal cancer, intestinal cancer, colon cancer, colorectal cancer, kidney cancer, clear cell renal cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, prostate cancer, testicular cancer, skin cancer, melanoma, large cell lung cancer, triple-negative breast cancer, lymphoma, and small cell lung cancer. More preferably, the tumor or cancer is a tumor or cancer that expresses DLL3. use.

Images